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To measure is to know.  
If you cannot measure it, you cannot improve it. 
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SUMMARY 
 
Economic evaluations of health care technologies are now commonly carried out 
to assess the economic value of new pharmaceuticals, medical devices and 
procedures. The growing number of economic evaluations reflects both 
widespread interest in economic information for new technologies and the 
regulatory and reimbursement requirements of many countries. The aim of 
health economic evaluations is to measure, value and compare the costs and 
benefits of different health care interventions. To date, cost-effectiveness analysis 
(CEA) and cost-utility analysis (CUA) are the two types of economic evaluations 
that are applied in the vast majority of economic evaluation studies. 
Cost-effectiveness estimates in CEAs and CUAs can either be derived from data 
collected alongside a randomized controlled clinical trial or by means of decision 
analytic modelling. In recent years, there has been a trend towards increasing 
incorporation of economic evaluations within randomized controlled trial. Trial-
based economic evaluations will be efficient for answering economic questions for 
diseases or treatments where the bulk of costs derive from primary outcomes that 
are measured in the trial and for which the quality of life impacts are persistent, 
and thus can be measured infrequently.  
In situations where evidence from a trial is insufficient to address a certain 
decision problem (e.g.  short time horizon of the trial; small sample size), decision 
analytic modelling provides a structure within which evidence from a range of 
sources can be directed at a specific decision problem for a defined population 
and context. Decision analytic models use mathematical relationships to define a 
series of possible consequences. Based on the inputs into the model, the 
likelihood of each consequence is expressed in terms of probabilities. Costs and 
outcomes are linked to each consequence. It is thus possible to calculate the 
expected costs and expected outcome for different interventions analyzed in the 
model.  
In the first study the cost-effectiveness of extended prophylaxis with 
fondaparinux of one month versus one week in patients undergoing hip fracture 
surgery and total hip replacement was analysed. The analysis was based on a 
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decision tree model that allowed to compare costs from a health care perspective 
and health effects for both strategies using a time horizon of 30 days and 5 years. 
In this cost-effectiveness analysis the health effect was measured in life-years 
gained. Depending on the patient population and the time horizon, the extended 
prophylaxis with fondaparinux was found to be cost-effective or cost-saving (i.e. 
the extended prophylaxis was more effective and less costly). Uncertainty in 
various clinical and cost input parameters was explored by univariate sensitivity 
analysis and showed that reasonable changes in the parameters’ values had only a 
small effect on the cost-effectiveness estimates.  
In the second study the cost-effectiveness of risedronate was examined for Swiss 
osteoporotic women. Several clinical trials and meta-analyses proved the efficacy 
of risedronate in reducing the number of fractures at the hip, wrist and vertebra. 
A limitation of the published trials is that the range of the age of the enrolled 
patients is relatively small and on average around 70 years. From epidemiological 
data it is well established, however, that for osteoporotic women, the fracture risk 
is strongly dependent on age. The fracture risk in women who had a previous 
fracture is further increased compared to the fracture risk in osteoporotic women 
without a previous fracture. In this study we developed a time-dependent Markov 
model to examine the cost-effectiveness of risedronate for women who start a 5 
year risedronate therapy between 60 and 90 years of age. This cost-utility 
analysis was carried out from a Swiss health care perspective using a lifetime time 
horizon. For osteoporotic women or women with severe osteoporosis we found 
that risedronate treatment is cost-effective. As expected, the cost-effectiveness 
estimate is influenced by the patients’ age and disease severity.  
Two chapters of this thesis are based on a cost-utility analysis of 2 drug-eluting 
stents (the sirolimus- and the paclitaxel-eluting stent; DES) compared to bare 
metal stents (BMS). Since their approval in 2003, drug-eluting stents have 
revolutionized the care for patients with acute or symptomatic coronary heart 
disease. Clinical trials have demonstrated a striking reduction in angiographic 
restenosis and revascularization rates with drug-eluting stents. As a consequence 
the majority of coronary interventions are today performed with drug-eluting 
stents. Although DES are now used for several years, concerns remain about their 
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long term safety. Given the threefold higher acquisition costs, it was unclear 
whether DES are cost-effective when compared to BMS. Based on clinical data 
with 3-year follow-up we developed a Markov cost-utility model to shed light on 
this question. Both DES under analysis were found to not be cost-effective from a 
US Medicare payer’s perspective. Although revascularisation rates were lower in 
DES patients, the gain in quality-adjusted life years was very small (for the 
sirolimus-eluting stent) or negative (for the paclitaxel-eluting stent). Given the 
uncertainty in the input parameters, the decision uncertainty is large.  
In a further study the decision uncertainty was examined in full depth. With 
expected value of perfect information (EVPI) analysis total decision uncertainty 
was assessed. EVPI provides the value a rational decision maker should be willing 
to spend in order to acquire perfect information (i.e. to eliminate parameter 
uncertainty). Through expected value of partial perfect information analysis the 
contribution of groups of parameters towards total decision uncertainty was 
examined. The uncertainty in the cost-effectiveness estimate is largely driven by 
the uncertainty in the clinical model input parameters. More precise clinical 
parameter estimates could be derived from a future clinical trial. To assess the 
value of such a trial, analysis of expected value of sample information was 
performed. Although the value of a future trial would be enormous, we show 
diminishing marginal returns and a linear increase in the costs of the future trial 
per additional patient enrolled into the trial for sample sizes larger than 2000 
patients. The optimal sample size was estimated to be 4700 patients for a 3 year 
time horizon.  
To conclude, decision analytic models have a range of uses and are thus an 
important and powerful tool for economic evaluations in health care. Decision 
analytic models that incorporate probabilistic sensitivity analysis and closely 
related expected value of perfect information analysis are best suited to provide 
decision makers not only with a point estimate for the cost-effectiveness estimate 
but to quantify in addition decision uncertainty and the value of future research.  
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ZUSAMMENFASSUNG 
 
Gesundheitsökonomische Evaluationen werden heutzutage standardmässig 
eingesetzt, um den ökonomischen Wert von neuen Arzneimitteln, medizinischen 
Geräten und Verfahren zu ermitteln. Die wachsende Anzahl von veröffentlichten 
gesundheitsökonomischen Evaluationen spiegelt sowohl das weitverbreitete 
Interesse an ökonomischen Informationen über neue Technologien wider, als 
auch die Notwendigkeit solcher Daten für die Zulassung und Erstattungsfähigkeit 
dieser Technologien. Das Ziel der gesundheitsökonomischen Evaluationen ist es, 
die Kosten und den Nutzen verschiedener Interventionen zu messen, zu bewerten 
und zu vergleichen. Die in ökonomischen Evaluationen am häufigsten 
verwendeten Studientypen sind die Kosten-Effektivitäts-Analyse (CEA) und die 
Kosten-Nutzwert-Analyse (CUA).  
Für die CEA und die CUA werden Kosteneffektivitätsschätzer von Daten die in 
einer randomisierten klinischen Studie erhoben wurden oder mittels eines 
entscheidungsanalytischen Modells abgeleitet. In den letzten Jahren hat sich ein 
Trend zur vermehrten Integration von ökonomischen Evaluationen in 
randomisierte klinische Studien abgezeichnet. Studienbasierte ökonomische 
Evaluationen sind effizient, wenn ökonomische Fragen für Krankheiten oder 
Behandlungen beantwortet werden sollen, bei denen der Grossteil der Kosten 
durch Ergebnisse anfällt, die innerhalb der Studie gemessen werden können und 
bei denen gleichzeitig die Lebensqualität gleichbleibend ist.  
In verschiedenen Situationen (z.B. kurzer Zeithorizont der Studie; kleine Anzahl 
an Studienteilnehmern) sind Daten von klinischen Studien unergiebig, um 
bestimmte Entscheidungsprobleme anzugehen. Hier, stellen 
entscheidungsanalytische Modelle eine Möglichkeit Daten aus verschiedenen 
Quellen für ein bestimmtes Entscheidungsproblem für eine definierte Population 
und einen bestimmten Kontext zu synthetisieren. Entscheidungsanalytische 
Modelle benutzen mathematische Zusammenhänge um die Konsequenzen 
verschiedener Behandlungsstrategien aufzuzeigen. Durch die Eingangswerte des 
Modells wird die Wahrscheinlichkeit des Eintretens dieser Konsequenzen durch 
Wahrscheinlichkeitswerte ausgedrückt. Für jede Konsequenz werden Kosten und 
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Effekte bestimmt. Dadurch ist es möglich, die erwarteten Kosten und die 
erwarteten Ergebnisse für verschiedene Interventionen, die mit dem Modell 
analysiert werden, zu bestimmen.  
In der ersten Studie wurde die Kosteneffektivität von verlängerter Fondaprinux-
Prophylaxe von einer Woche bis zu einen Monat für Patienten im Rahmen einer 
Enscheidungsanalyse untersucht, die sich einem chirurgischen Eingriff an der 
Hüfte unterziehen mussten oder bei denen die Hüfte komplett ersetzt wurde. Für 
beide Strategien wurden die Kosten aus der Krankenkassen-Perspektive sowie die 
Gesundheitseffekte bei einem Zeithorizont von 30 Tagen und 5 Jahren analysiert. 
In dieser Kosten-Effektivitäts-Analyse wurde der Gesundheitseffekt anhand 
gewonnener Lebensjahre gemessen. Abhängig von der Patientenpopulation und 
vom Zeithorizont war die verlängerte Prophylaxe mit Fondaparinux entweder 
kosteneffektiv oder kostensparend (d.h. die verlängerte Prophylaxe war 
gleichzeitig effektiver und günstiger). Mittels univariater Sensitivitätsanalyse 
wurde die Unsicherheit bezüglich verschiedener klinischer und kostenbezogener 
Eingangsparameter untersucht. Die Analyse zeigte, dass angemessene 
Veränderungen der Parameterwerte nur einen kleinen Effekt auf die 
Kosteneffektivitätsschätzer hatten. 
In der zweiten Studie wurde die Kosteneffektivität von Risedronat für 
osteoporotische Frauen in der Schweiz untersucht. In mehreren klinischen 
Studien und Meta-Analysen konnte gezeigt werden, dass Risedronat ein effektives 
Mittel ist, um Frakturraten der Hüfte, des Handgelenks und der Wirbelsäule zu 
reduzieren. Durch epidemiologische Daten gilt als gesichert, dass das 
Frakturrisiko stark vom Alter der Patientinnen abhängt. Des Weitern ist das 
Frakturrisiko derjenigen Frauen mit einer vorausgegangenen Fraktur im 
Vergleich zu Frauen ohne vorausgegangene Fraktur deutlich erhöht. In dieser 
Studie wurde ein zeitabhängiges Markovmodell entwickelt, um die 
Kosteneffektivität einer 5-jährigen Risedronattherapie bei Frauen, die im Alter 
von 60 bis 90 Jahren mit der Therapie beginnen zu untersuchen. Für 
osteoporotische Frauen oder Frauen mit schwerer Osteoporose ist die 
Behandlung mit Risedronate kosteneffektiv. Wie zu erwarten, wurde der 
Zusammenfassung 
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Kosteneffektivitätsschätzer durch das Alter der Patienten und den Schweregrad 
der Erkrankung beeinflusst.  
Zwei Kapitel dieser Dissertation basieren auf einer Kosten-Nutzwert-Analyse von 
Arzneimittel-freisetzende Stents (Sirolimus- und Paclitaxel-freisetzende Stents; 
DES) im Vergleich zu herkömmlichen Metallstents (BMS). Seit ihrer Zulassung 
im Jahr 2003 haben die Arzneimittel-freisetzenden Stents die Behandlung der 
akuten und symptomatischen koronaren Herzkrankheit revolutioniert. In 
klinischen Studien konnten beachtenswerte Verminderungen in 
angiographischen Restenose- und Revaskularisationsraten gezeigt werden. Dieser 
Ergebnisse haben dazu geführt, dass die Mehrzahl der Koronarinterventionen 
heutzutage mit Arzneimittel-freisetzenden Stents durchgeführt werden. Trotz des 
schon mehrjährigen Gebrauchs der DES gibt es jedoch immer noch Bedenken 
bezüglich ihrer langfristigen Sicherheit. Da zudem die Beschaffungkosten von 
DES im Vergleich zu BMS rund dreifach höher sind, wird die Kosteneffektivität 
von DES je nach Modellansatz in der Literatur kontrovers diskutiert. Wir 
entwickelten basierend auf klinischen Daten mit 3-jährigem Follow-up - ein 
Markov Kosten-Nutzwert-Modell um die Kosten-Effektivität von CES im 
Vergleich zu BMS für die US amerikanischen Verhältnisse zu untersuchen.  Wir 
zeigen, dass aus Sicht der US amerikanischen Krankenkasse Medicare beide DES 
nicht kosteneffektiv sind. Obwohl die Revaskularisationsraten bei DES-Patienten 
niedriger waren, war schlussendlich der Gewinn an qualitätsadjustierten 
Lebensjahren sehr gering (für den Sirolimus-freisetzenden Stent) oder negativ 
(für den Paclitaxel-freisetzenden Stent). Aufgrund von hoher Unsicherheit bei 
den Eingangsparametern war die Entscheidungsunsicherheit in unserem Model 
jedoch gross. 
In einer weiteren Studie wurde deshalb die Entscheidungsunsicherheit durch eine 
Analyse des erwarteten Wertes von perfekter Information (EVPI) weiter 
untersucht. EVPI bestimmt den Wert, den ein rationaler Entscheidungsträger zu 
zahlen bereit sein sollte, um perfekte Information zu erhalten (d.h. unter 
Ausschaltung von Parameterunsicherheit). Mittels einer Analyse des erwarteten 
Wertes von partiell perfekter Information wurde bestimmt, inwieweit einzelne 
Parametergruppen zur gesamten Entscheidungsunsicherheit beitragen. Die 
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Unsicherheit der Kosteneffektivitätsschätzer wird grösstenteils durch die 
Unsicherheit in den klinischen Inputparametern des Modells bestimmt. Präzisere 
Schätzer für die klinischen Parameter könnten prinzipiell durch eine zukünftige 
klinische Studie erlangt werden. Der Wert einer solchen Studie wurde durch eine 
Analyse des erwarteten Wertes von Stichprobeninformation ermittelt. Auch 
wenn der Informationswert einer zukünftigen Studie wichtig ist, zeigt sich bei 
abnehmendem Grenzertrag pro zusätzlich eingeschlossenem Patienten, den 
gleichzeitig linear ansteigenden Kosten der zukünftigen Studie bei 
Stichprobenzahlen von mehr als 2000 Patienten dass die optimale 
Stichprobenzahl, bei einem Zeithorizont von 3 Jahren 4700 Patienten beträgt.  
Wir veranschaulichen, dass entscheidungsanalytische Modell eine Vielzahl von 
Anwendungen haben, und daher wichtige und nützliche Werkzeuge in 
gesundheitsökonomischen Analysen darstellen. Entscheidungsanalytische 
Modelle, welche probabilistische Sensitvitätsanalyse und eine Analyse des 
erwarteten Wertes von perfekter Information beinhalten, erlauben 
Entscheidungsträgern zudem die Entscheidungsunsicherheit und den Wert 
zukünftiger Forschung im Entscheidungsprozess zu berücksichtigen.  
 
 
 
 
 
19 
 
 
 
 
  
Chapter 1: Introduction 
 
20 
 
 
CHAPTER 1: INTRODUCTION 
 
The introduction of new pharmaceuticals, medical devices or procedures in the 
last decades has lead to unprecedented improvements in health outcomes in 
many the northwestern hemisphere (1). Unfortunately the majority of advances in 
medical technology comes at higher costs than the currently used technologies, or 
add new costs to the health care budget for previously unavailable treatments (2; 
3). As a consequence, spending on health care has been rising in many countries 
of the western world at a faster rate than the increase in the gross domestic 
product (4; 5).    
Economic evaluations are now routinely used in many countries for the 
evaluation of health technologies and for decision making on reimbursement 
policy (6-8). This development has favored very important methodological 
advances in economic evaluation for health care decision making (9-12). The 
general concepts of modern economic health care evaluations and some of the 
advanced concepts are presented in this chapter and applications are shown in 
the following chapters.  
 
The decision problem 
In its simplest form, economic evaluations compare two treatments strategies 
against each other on the basis of expected costs (C)  and expected health 
outcomes (E)(13). The ratio of the expected cost difference (incremental costs) 
over the expected difference in health effects (incremental effect) is termed the 
incremental cost-effectiveness ratio (ICER) and is a standard cost-effectiveness 
estimate that is presented in almost every economic evaluation published to date: 
   	
	 
  	
	 
     
Δ
Δ 
Types of economic evaluations 
Different types of economic evaluations exist to date. The three most prominent 
types are cost-benefit analysis, cost-effectiveness analysis and cost-utility 
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analysis (13-17). All three analyses measure costs in monetary units (e.g. in US$ 
or CHF), but differ in the way health outcomes are measured. In a cost benefit-
analysis, the oldest form of economic evaluations, health outcomes are measured 
in monetary units as are costs. In contrast, in a cost-effectiveness analysis 
(applied in chapter 2) health outcomes are measured in natural units (e.g. life-
years gained, event prevented, mmHg blood pressure lowered). Although useful 
within disease areas, economic evaluation can only be applied to its fullest 
strength, if comparisons between disease areas are possible (13). This is not the 
case with cost-effectiveness analysis (with the exception of life-years gained as the 
unit of health outcome). For decision making purposes within the whole health 
care sector, a decision maker would for example need to know the relative value 
of preventing a hip fracture in osteoporotic patients (see chapter 3) compared to 
the value of avoiding the need for a repeat revascularisation procedure in 
interventional cardiology (see chapter 5). This problem can be avoided when 
health outcomes for all disease areas are measured in the same generic unit. 
Several different generic units have been proposed (e.g. healthy years equivalent 
(HYE), quality adjusted life years (QALY), disability adjusted life years (DALY)). 
QALYs are generally the most used generic measure (18).  
 
Clinical trials vs. decision analytic models 
Economic evaluations of health care interventions are usually based on data from 
a single randomized controlled trial (RCT) or use decision analytic modelling 
(13;19). Since 1994, approximately 30% of published economic evaluations have 
been based on data from a single RCT (19). It has been argued, that trial-based 
economic evaluation is a limited framework for cost-effectiveness analysis. Main 
concerns relate to the failure of most trials to compare all relevant options, the 
limited time horizon, the lack of relevance to the decision context, the failure to 
incorporate all evidence and the inadequacy to allow for the quantification of 
decision uncertainty (19). An alternative to trial-based economic evaluations are 
economic evaluations based on decision analytic modelling. The use of decision 
analytic models in economic evaluations is the only framework that has the 
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potential to meet all the requirements for economic evaluation for decision 
making (20).   
 
Model types 
The choice of the model type and structure used in an economic evaluation based 
on a decision analytic model is dependent on the features of the 
disease/technology under analysis (20; 21). These features include, for example, 
the timing of the occurrence of health-related events or whether the assumption 
of a constant effect of the intervention over time holds to be true. The two most 
prominent model types are decision trees and Markov models (see appendix) (13; 
20-23).  
 
Probabilistic sensitivity analysis 
In probabilistic sensitivity analysis (PSA) the joint implication of parameter 
uncertainty on the cost-effectiveness estimate is analysed (24). Hence, in PSA, 
probability distributions are assigned to those parameters that could in principle 
be sampled. In decision analytic models, these parameters are often clinical 
parameters (e.g. relative risk estimates, transition probabilities), cost parameters 
or quality of life parameters (24-27). The assigned distribution should reflect the 
prior beliefs concerning the uncertainty in the parameters’ uncertainty (20). 
Although numerous types of probability distributions exist, their choice is not 
arbitrary and should incorporate logical bounds on the parameter values. As for 
example cost parameters cannot be negative, a gamma distribution is an 
appropriate choice to reflect uncertainty in cost parameters, since the gamma 
distribution is bound to be non-negative. A beta distribution is a legitimate choice 
to reflect parameter uncertainty in (transition) probability parameters since both 
the beta distribution and probability parameters are bound to the interval zero to 
one. The most likely probability distribution (i.e. the distribution’s 
hyperparameters) from the infinite number of beta, gamma or other probability 
distributions can be obtained by the method of moments fitting.  When expected 
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values (i.e. mean values) and corresponding variances are known the equations 
below can be solved to obtain the hyperparameters α and β of a beta or gamma 
distribution (see appendix) (28).  
The uncertainty of input values in a given model is then analyzed by means of 
Monte Carlo simulation, whereby random values of the model input parameters 
are simulated and the model is run for each simulated parameter set (29). The 
resulting sample of outputs (e.g. net monetary benefit of an intervention) 
characterizes the output uncertainty. In order to obtain accurate estimates, 
typically 1000 or more model runs (iterations) are necessary (30).  The output of 
a probabilistic sensitivity analysis is often presented by the cost-effectiveness 
acceptability curve, that estimates the probability that the intervention under 
analysis is cost-effective for various willingness-to-pay values (31-33).  
 
Value of information 
Decisions should be based on expected cost-effectiveness given the existing 
information (i.e. on the mean value of the cost-effectiveness estimate) (34). Yet, 
decisions based on existing information will be uncertain, and there will always 
be a chance that the wrong decision will be made (i.e. an intervention will be 
adopted when in fact it is not cost-effective).  
To reduce decision uncertainty, a rational decision maker may thus wish to base 
the decision on a more sound evidence base (35). Expected value of perfect 
information analysis (EVPI) and expected value of partial perfect information 
analysis (EVPPI) analysis provides information on the contribution of single 
parameters or groups of parameters towards total decision uncertainty (36-38). 
Hence, EVPPI allows to identify those parameters for which further information 
is of highest value to reduce total decision uncertainty. In many situations, 
further information will only be available from clinical trials. Given that the cost 
of conducting a clinical trial is large and increases with sample size, the net 
benefit of the future clinical trial will ultimately yield diminishing marginal 
returns with increasing sample size (34). The optimal sample size for the future 
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clinical trial can thus found by identifying the sample size that maximises ENBS 
(37).   
Appendix 
 
Markov models 
A Markov model is a discrete-time stochastic process with the Markov property 
(39-41). The Markov property refers to the fact that future states in the model are 
independent of the present state.   
 
Figure 4. Example of a Excel worksheet with a simple Markov model. 
100 patients are defined to be in the health state “well” at cycle zero. Based on the 
transition probabilities (cells C22 to D23) patients face the risk of moving to the 
health states “sick” or “dead” each cycle. Cells B11 to D16 contain the actual 
model. The numerical values of cells B11 to D16 are shown in cells B2 to D7. 
Column E was included to record the total number of patients in the model over 
time (which should remain constant).   
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Method of moments fitting 
The method of moments fitting is used to derive hyperparameters for a given 
mean value and standard deviation (42). The hyperparameters define a unique 
probability distribution from the set of infinite probability distributions: 
 
Beta 
       
    ⋅          1 
  
Gamma 
     
   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Expected value of perfect information 
In decision making under uncertainty with unknown parameters , a rational 
decision maker should adopt the intervention j that has the highest expected net 
benefit (20). The optimal decision is the one that has the highest expected net 
benefit:   
 !"#$,  
Without parameter uncertainty, it true value of the unknown parameters  would 
be known and thus the expected benefit of the adopted strategy would always be 
equal to the maximum net benefit:  
!   "#$,  
The difference in expected benefit of the adopted decision without parameter 
uncertainty (i.e. perfect information) in parameters  and the net benefit of the 
decision given current information with uncertainty in parameters  is the 
expected value of perfect information: 
EVPI = !   "#$,  
  !"#$,  
As the absolute value in net benefit of a strategy is dependent on the number of 
patients that were analysed, so EVPI is likewise dependent on the number of 
patients for whom EVPI is calculated (20). Although it may be useful to compare 
parameter uncertainty per single patient (or thousands of patients) across 
different decision problems,  the absolute value of perfect information can only be 
obtained by multiplying the number of patients entering the decision problem 
with the EVPI per patient: 
population EVPI = EVPI · & /1   
(),,…,+
 
To account for the timing of the occurrence of new patients the incidence rate I 
has to be discounted at a discount rate r per period t.  
Expected value of partial perfect information 
In almost every situation a decision maker will encounter several unknown 
parameters (,, -. To compare the relative impact the unknown parameters have 
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on overal decision uncertainty the expected value of partial perfect information 
can be calculated (36-38). This approach the yields the value of perfect 
information in one parameter , (or one group of parameters) while the true 
values of the other parameters - will remain unknown. For a given value of ,, a 
rational decision maker would choose the intervention j that provides the highest 
expected net benefit:  
 .|0"#$, ,, - 
Given perfect knowledge about parameter ,, the expected benefit of the decision 
taken can be obtained by averaging the maximum expected net benefits over the 
distribution of  ,: 
,  .|0"#$, ,, - 
The expected benefit of the decision given current information is the same as 
above: 
 !"#$,  
Consequently EVPPI is obtained by calculating the difference between the 
expected value of the decision made with perfect information in parameter , and 
the value of the decision given all the current level of uncertainty: 
EVPPI0   ,  .|0"#$, ,, - 
  !"#$,   
Although in principle the EVPPI calculation is similar to the calculation of EVPI, 
the computation of EVPPI is far more complex since there are two levels of 
uncertainty that have to be addressed simultaneously (36; 38). The first level of 
uncertainty arises from the imperfect knowledge about the parameter of interest 
,. Even in light of perfect information in the true value of parameter , it would 
still not be known how uncertainty in the other parameters - will resolve. 
Unfortunately EVPPI can thus only be calculated by using a 2-level sampling 
algorithm. In the outer loop simulation a value of  , is sampled from its prior 
distribution. Given this sampled values for ,, uncertainty in parameters - have to 
be assessed in an inner loop. 
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Box 1. 2-Level EVPPI algorithm 
 
 
EVPPI = "#|perfect  information 
  "#|current information 
Calculation of Net Benefit of the baseline decision  
1) set up a decision model that compares two strategies 
2) characterize uncertain parameters with probability distributions 
3) use Monte Carlo simulation with a large number of iterations (e.g. 
10 000) to collect a sample set of the uncertain parameter values; the 
baseline adoption decision is the strategy that has the highest expected 
net benefit 
 
2-Level EVPPI algorithm 
 
4) sample the parameter of interest once from its prior distribution (outer-
level simulation) 
5) sample the remaining parameters with a Monte Carlo simulation 
multiple times (inner-level simulation; e.g. 1000 times), while holding 
the value of the parameter of interest fixed at its sampled value; 
calculate the conditional expected net benefit for the two strategies by 
averaging over the inner-level simulation values; the revised adoption 
decision is the one with the highest expected net benefit given the 
sampled value (outer-level simulation) of the parameter of interest 
6) loop back and repeat steps 4 and 5 multiple times (e.g. 1000 times); 
then calculate the expected net benefit of the revised adoption decision 
(outer-level simulation) by averaging over the expected net benefit of the 
revised adoption decisions from the inner-level simulations  
7) calculate EVPPI by subtracting the net benefit of the baseline adoption 
decision from the net benefit of the revised adoption decision:   
 
 
 
 
Chapter 1: Introduction 
 
29 
 
 
 
Expected value of sample information 
 
The expected benefit of sample information (i.e. the value of a future clinical trial) 
can be regarded as the resulting reduction in the cost of uncertainty surrounding 
the choice between different treatment alternatives. Given that incremental net 
benefit is normally distributed, the expected benefit of sample information can be 
calculated as follows (20): 
 
EVSI|A,A   B ⋅  CV|A,A  ⋅  D0 ⋅ FG|A,A 
 
D|A,A   |H0|/ D0 ⋅  CIV|A,AJ 
 
V|A,A   DK/DK  D

A   D
  D)

A-A  
 
 A = total sample size of the future trial 
A = size of the ‘new intervention’ trial arm 
B = threshold value 
F = unit normal loss integral 
H0 = prior mean net health benefit 
D = variance of the net benefit of the new intervention 
D) = variance of the net benefit of the old intervention 
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Population EVSI 
Similar to the calculation of population EVPI, the population EVSI is calculated 
by multiplying per patient EVSI with the incidence of patients (I) in each period 
(t) discounted at rate (r). Patients who are enrolled in the trial will not be able to 
benefit from the sample information (i.e. the gain in information obtained by the 
trial) (20):  
population EVSI = EVSI|A,A · &  
 A/1   
(),,…,+
 
 
Expected net benefit of sampling 
Assuming that the trial costs comprise fixed costs (Cf; i.e. for the data analysis) 
and variable reporting costs (Cr), the costs of the future trial are calculated as 
follows: 
 
cost of sampling = Cs|A,A = Cf + (- )) ⋅ A + Cr ⋅ A 
 
The net benefit of sampling is the difference in the value of the future trial and its 
estimated costs (20): 
 
ENBS|A,A   EVSI|A,A 
 Cs|A,A  
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CHAPTER 2: FONDAPARINUX 
Cost-effectiveness of extended venous thromboembolism 
prophylaxis with fondaparinux in hip surgery patients  
 
Abstract 
Summary background data: Extended prophylaxis with the synthetic 
pentasaccharide fondaparinux for one month versus one week in hip fracture 
surgery has been shown to reduce the risk of venous thromboembolic events 
(VTE) by 96% in the Penthifra Plus trial. The cost-effectiveness of extended 
prophylaxis with fondaparinux still remains to be determined.  
Methods: We developed a decision analytic cost-effectiveness model comparing 
the use of fondaparinux for four weeks versus one week from a health care 
perspective. The analyses were performed for patients undergoing hip fracture 
surgery (HFS) and total hip replacement (THR). Efficacy data were extracted 
from published randomised controlled trials and natural history data after VTE 
from observational studies. Cost data were derived from the literature and other 
published sources. Costs were expressed in 2004 Swiss Francs (CHF) and effects 
as life-years gained (LYG).  
Results: In patients undergoing HFS, the incremental cost-effectiveness ratio 
(ICER) of extended four-week fondaparinux prophylaxis versus a one-week 
regimen was CHF 2801/LYG after 30 days, with cost-savings after 5 years. In 
patients undergoing THR, the respective ICER of extended fondaparinux 
prophylaxis was CHF 20294/LYG after 30 days, with cost-savings after 5 years.  
Conclusion: In our model, the substantial clinical benefit of extended 
thromboembolism prophylaxis with fondaparinux in major orthopaedic surgery 
translates into favourable cost-effectiveness figures in the short term and cost-
savings when a 5-year time horizon is used.  
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Introduction 
Patients undergoing major orthopaedic procedures such as hip fracture 
surgery (HFS) and total hip replacement (THR) are at increased risk of 
developing venous thromboembolic events (VTE)(1) such as deep vein 
thrombosis and (DVT) and pulmonary embolism (PE). Without prophylactic 
treatment, 36-60% of HFS patients and 47-57% of THR patients will develop a 
VTE . It has been estimated that 0,2% of PE following a DVT after surgery will 
lead to death. In addition, the long-term clinical course of DVT may be 
complicated by recurring episodes and post-thrombotic syndrome (PTS), which is 
associated with significant morbidity and costs (2;3). An estimated 20%-50% of 
patients with symptomatic DVT will develop a consecutive PTS within 1 to 2 years 
(4). Both DVT and PE may be silent and there may be no specific symptoms and 
signs, which may complicate the diagnostic work-up of patients. 
Fondaparinux is a synthetic pentasaccharide that has been shown to be 
effective in preventing thromboembolic events in patients undergoing hip 
fracture surgery as compared to enoxaparin in the Penthifra trial (5). The 
majority of symptomatic VTEs occurs after hospital discharge. Since the risk of 
VTE persists for up to 3 months after surgery, patients may benefit from extended 
prophylaxis. The efficacy of extended antithrombotic prophylaxis with 
fondaparinux for four weeks versus one week was evaluated in the Penthifra Plus 
trial (6). Extended fondaparinux prophylaxis reduced the incidence of VTE from 
35.0% to 1.4% (relative risk reduction of 95.9%, 95% CI:87.2%-99.7%). However, 
in times of increasing awareness about the scarcity of health care resources, 
considerations must also be given to whether extended fondaparinux prophylaxis 
represents value for money. The cost-effectiveness of extended prophylaxis with 
fondaparinux in major orthopaedic surgery in Switzerland still remains to be 
determined. We therefore estimated the cost-effectiveness of a four-week 
fondaparinux regimen versus a one-week regimen from a health care perspective 
using a decision analytic model.  
Methods 
An international decision analytic cohort simulation model developed in 
Microsoft Excel® was used to compare a four-week fondaparinux regimen with a 
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one-week regimen in patients undergoing THR or HFS in Switzerland. The model 
describes the clinical pathway in terms of conditional probabilities of events and 
the associated costs, and estimates the total effects and costs for each treatment 
option. The difference in costs between the two regimens (i.e., incremental costs) 
are then divided by the difference in effects (i.e., incremental effects) and 
expressed as costs per life-year gained (i.e., incremental cost-effectiveness ratio). 
The analysis was conducted from the Swiss health care perspective, only health 
care costs were therefore considered in our analysis. Future costs and health 
outcomes were discounted using an annual discount rate of 4% (7;8). We used a 
time horizon of 30 days and 5 years in our analysis. The shorter time horizon 
reflects the immediate benefit of extended fondaparinux prophylaxis and 
coincides with the time horizon of the Penthifra Plus trial. A longer time horizon 
of 5 years was used to reflect the long-term benefit of fondaparinux prophylaxis in 
terms of recurrent VTE and postthrombotic syndrome (PTS) prevented, a chronic 
disease associated with substantial costs. 
 
Model structure 
 Patients undergoing HFS or THR are at risk of VTE. In the model, all 
patients are assumed to receive fondaparinux immediately after surgery. The 
prophylactic treatment is provided to all patients for 7 days. Only patients 
without symptomatic VTE events are eligible for extended prophylaxis with 
fondaparinux for an additional three weeks. Patients who receive prophylaxis 
during the entire extended period may experience a DVT until day 30. Between 
day 30 and day 90, a small proportion of DVT patients will have developed a 
symptomatic VTE (either DVT or fatal/non-fatal PE). Patients who do not receive 
extended fondaparinux prophylaxis (i.e., receive only a one week fondaparinux 
regimen) follow the same clinical pathways but are at increased risk of VTE. For 
the period after day 90 until the end of year 5, patients were assumed to be at risk 
of recurrent VTE and/or of post-thrombotic syndrome. Patients who experienced 
a clinically symptomatic DVT and PE are assumed to be at risk of recurrent VTE 
and PTS. Those with subclinical DVT are only assumed to be at risk of PTS. 
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Clinical model parameters 
Event probabilities were derived from clinical trials and the published 
literature (see Table 1). Rates of subclinical DVT and PE at day 30 were taken 
from the Penthifra Plus trial (6). Rates of subclinical DVT for THR patients were 
taken from Eikelboom et al. (9). The risk of clinical VTE at day 7 was obtained 
from the Penthifra Plus trial for HFS patients (6). For THR patients a rate was 
obtained by using an estimated rate for enoxaparin treated patients (9) that was 
adjusted for the relative risk of fondaparinux by using the risk ratio published by 
Lassen et al. (10) and Turpie et al. (11). Rates for clinical VTE for the period from 
day 7 to day 30 for THR patients under short term and extended prophylaxis 
were also obtained from Eriksson et al. (6). Among THR patients, the rate of 
clinical VTE was derived from data published by Gordois et al. (12) and Eriksson 
et al. (6). Clinical rates of VTE for the time that falls beyond the time horizon of 
the published trials (30 days) were calculated by using a study that analysed the 
temporal pattern of VTE (13).    
Although the event rates were reported as combined VTE rates (for DVT 
and PE together), the model was set up to differentiate between DVT and PE. 
Using data from Eriksson et al. (5;6), it was assumed for HFS patients with a 
VTE, that 62.5% will develop a DVT and 37.5% a PE. Similarly, 71.3% of the THR 
patients with a VTE were assumed to have a DVT, the remaining 28.7% were 
assumed to be PE cases (14;15). The risk of major bleeding following prophylaxis 
was taken from trial data (6). A false-positive rate was applied to assess patients 
incorrectly suspected of having a DVT or PE (16;17). The false-positive rates were 
assumed to be the same for both types of prophylaxis and both HFS and THR 
patients. The risk of recurrent VTE was estimated from a long-term follow-up 
study of patients with objectively verified symptomatic DVT (18). The risk of PTS 
for patients who developed a clinical VTE during the first 90 days was taken from 
Prandoni et al. (2). Among patients who had a subclinical VTE, the risk of PTS 
was based on the incidence of PTS among orthopaedic surgery patients with 
venographically detected DVT in two retrospective studies (19;20).  
For HFS patients, the risk of death was taken from the Penthifra and the 
Penthifra Plus trial (5;6). The risk of death for THR patients was derived from  
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Probabilities HFS THR Reference 
    
All patients: 
   
Symptomatic VTE initial 7 day period 0.0068 0.0039 (6;9) 
False-positive DVT 0.1 0.1 (16;17) 
False-positive PE 0.02 0.02 (16;17) 
Death due to fatal PE 0.64 0.0145 (5;6;14;15;21;22) 
Death due to recurrent VTE 0.1231 0.0279 (2) 
PTS pts. with clin. DVT or PE day 90 – year 1 0.1730 0.1730 (2) 
PTS pts. with clin. DVT or PE year 2 0.0550 0.0550 (2) 
PTS pts. with clin. DVT or PE year 3+ 0.0173 0.0173 (2) 
PTS pts. with subclin. DVT day 90 to year 1 0.0722 0.0722 (19;20) 
PTS pts. with subclin. DVT year 2 0.0229 0.0229 (19;20) 
PTS pts. with sublin. DVT year 3+ 0.0072 0.0072 (19;20) 
Recurrent VTE day 1 to day 30 0.0018 0.0018 (12;18) 
Recurrent VTE day 31 to day 90 0.0036 0.0036 (12;18) 
Recurrent VTE day 91 to year 5  0.0397 0.0397 (12;18) 
Extended prophylaxis patients: 
   
Symptomatic VTE before day 30 0.0031 0.0028 (6) 
Subclinical VTE day 7 to day 30 0.0114 0.0045 (6;12) 
Symptomatic DVT day 30 to day 90 0.0388 0.1058 (13) 
Bleeding index>2 day 1-7 0.018 0.026 (5;6;10;11) 
Bleeding index>2 day 8-30 0 0 (5;6;10;11) 
Major Bleeding day 1-7 0.004 0.003 (5;6;10;11) 
Major Bleeding day 8-30 0.006 0.006 (5;6;10;11) 
Patients without extended prophylaxis: 
   
Symptomatic VTE before day 30 0.0273 0.0252 (6) 
Subclinical VTE day 7 to day 30 0.3227 0.1095 (6;12) 
Symptomatic DVT day 30 to day 90 0.0388 0.1058 (13) 
Bleeding index>2 day 1-7 0.018 0.026 (5;6;10;11) 
Bleeding index>2 day 8-30 0.018 0.018 (5;6;10;11) 
Major Bleeding day 1-7 0.004 0.003 (5;6;10;11) 
Major Bleeding day 8-30 0.006 0.006 (5;6;10;11) 
 
Table 1. Probabilities of events in the model (HFS=hip fracture surgery; THR= 
total hip replacement; VTE= venous thromboembolic event;  DVT=deep vein 
thrombosis;  PE=pulmonary embolism;  pts.=patients; clin.=clinical; 
subclin.=subclinical). 
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published sources (14;15;21;22). The risk of death from other causes for THR 
patients  was assumed to be the same as for the general population, adjusted for 
age and sex (23). The risk of death for HFS patients was estimated from Todd et 
al. (24).  
For THR patients it was assumed that life expectancy would not differ from the 
life expectancy of the general population. Since hip fractures are associated with 
increased mortality, life expectancy for HFS patients was assumed to be 25% 
lower as compared to the general population (25).  
The length of the initial prophylaxis was 7 days for both THR and HFS 
patients. Patients who received extended prophylaxis were modelled to receive 
prophylaxis for an additional 21 days. The average length of inpatient stay (LOS) 
was assumed to be 13.4 days for THR patients and 12.3 days for HFS patients 
based on the LOS of APDRG 209 (THR) and 211 (HFS)(26). The average age of 
patients of the cohort was modelled to be 65 for THR patients and 76.6 for HFS 
patients, based on values of the four trials that were mainly used as a source for 
the model input parameters (5;6;10;11). The average life expectancy was assumed 
to be 82.8 years for THR patients and 84 years for HFS patients (23;25).  
 
Cost data            
All costs were expressed in 2004 Swiss Francs (CHF). Table 2 shows a 
summary of the major cost parameters used in the model. Since Switzerland has a 
decentralized health care system, hospitalization costs may substantially differ 
between hospitals in the different Cantons in Switzerland, with in-patient costs 
often being reimbursed on a per diem basis independent of the disease category. 
Reimbursement schedules based on the DRG system are currently being 
considered, and further developed, as a method to more appropriately estimate 
resource consumption in Swiss hospitals, taking severity of disease and the 
disease category into account. We therefore estimated per diem hospitalisation 
costs using cost weights and average LOS data provided by APDRG Switzerland 
for each DRG (APDRG version 4.1 data)(26). The respective cost weight is then 
multiplied   with  CHF 9’041  for  university  hospitals  or  CHF  6842  for  non- 
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Surgery  Event Diagn. Time of 
occurrence 
Calculation Total 
cost  
THR PE Conf. IP THR with acute cor pulmonale (DRG 558) minus THR without 
complication (DRG 209); follow up costs 11'120 
THR PE Conf. PD Assumption all patients hospitalised (DRG 78); follow up costs 11'753 
THR PE Susp. IP Complete blood count; Prothrombin Time (PT) assay (Quick); blood chemistry; D-Dimer test; ultrasound scan of the leg; 
spiral CT scan 
732 
THR PE Susp. PD Complete blood count; Prothrombin Time (PT) assay (Quick); blood chemistry; D-Dimer test; ultrasound scan of the leg; 
spiral CT scan; hospitalisation 
991 
THR DVT Conf. IP Hip procedure with complications (DRG 210) minus hip procedure without complications (DRG 211); follow up costs 2125 
THR DVT Conf. PD Assumption 50% hospitalised (DRG 128); outpatient treatment 
reduces costs by 64% (29) 5621 
THR DVT Susp. IP Complete blood count; Prothrombin Time (PT) assay (Quick); blood chemistry; D-Dimer test; ultrasound scan of the leg 394 
THR DVT Susp. PD Complete blood count; Prothrombin Time (PT) assay (Quick); blood chemistry; D-Dimer test; ultrasound scan of the leg; 
hospitalisation 
653 
HFS PE Conf. IP HFS with acute cor pulmonale (DRG 558) minus HFS without 
complication (DRG 211); follow up costs 13'832 
HFS PE Conf. PD same as for THR patients 11'753 
HFS PE Susp. IP same as for THR patients 732 
HFS PE Susp. PD same as for THR patients 991 
HFS DVT Conf. IP same as for THR patients 2125 
HFS DVT Conf. PD same as for THR patients 5621 
HFS DVT Susp. IP same as for THR patients 394 
HFS DVT Susp. PD same as for THR patients 653 
Both PTS acute  PD Data from Perone (29) for procedure; follow up costs 5056 
Both PTS 
chronic 
 PD Data from Perone (29); costs as costs per 3 month 787 
Both BI>2  PD Hospitalisation; Complete blood count; Prothrombin Time (PT) 
assay (Quick); Chemogramm; blood replacement (2 units) 
736 
Both MB  PD Data from Perone (29) 11'661 
 
Table 2. Unit costs for the procedures. Costs in CHF (year 2004; adjustment to 
2004 prices using the consumer price index for health care in Switzerland) per one 
procedure (THR=total hip replacement; HFS=hip fracture surgery; Diagn.=Diagnosis; 
Conf.=confirmed diagnosis; Susp.=suspected diagnosis; IP=inpatient; PD=post 
discharge; PE=pulmonary embolism; DVT=deep vein thrombosis; PTS=post thrombotic 
syndrome; MB=clinical relevant major bleeding). 
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university hospitals (26). The cost of treating THR and HFS patients with 
suspected or confirmed DVT or PE was calculated as described in Table 2. 
Clinically relevant major bleeding was assumed to result in additional costs of 
CHF 11'661 (see table 2) for both patient groups. This figure was derived from the 
literature, and converted into 2004 Swiss Francs (CHF) using the consumer price 
index for health care.  
The cost for PTS was divided up into an acute part and follow-up costs per 
three-month period. We used the proportion of acute and chronic costs 
associated with PTS in relation to the post-discharge costs after DVT as reported 
by Lundqvist et al. (27) to estimate the costs associated with PTS in Switzerland, 
using post-discharge DVT cost estimates as reported by Perone et al. (28). 
The costs for diagnostic procedures (e.g. CT scans) and out-patient 
treatments were estimated using Tarmed version 1.1r (29). The required 
procedure for diagnostic workup was based on guidelines and expert opinion as 
shown in Table 2.  
The price of fondaparinux (Arixtra®) was obtained from the Swiss Drugs 
Compendium (30) to estimate the daily cost of the fondaparinux prophylaxis. It 
was assumed that both HFS and THR patients would receive 2.5 mg as a single 
dose per day (CHF 16.7 per day). It was assumed that extended prophylaxis would 
impose additional costs of CHF 23 per day for administering the drug by an 
outpatient nurse to 7.7% of the patients, who would not be able to self-inject 
fondaparinux after discharge (29). 
Sensitivity analysis 
A one-way sensitivity analysis was performed on major model parameters. 
Since costs were calculated for university hospitals in Switzerland in the base case 
analysis, DRG cost estimates from non-university hospitals were used to calculate 
the lower bound of the incremental cost-effectiveness ratio in a sensitivity 
analysis. This difference in costs between the base case and lower bound estimate 
was added to the base case value of the respective model input parameter to 
estimate the upper bound of the incremental cost-effectiveness ratio. The ranges 
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used for the cost and clinical parameters in the sensitivity analyses are shown in 
Table 3 and Table 4. 
The discount rate was also varied between 0% and 8% to assess the impact 
of different time preferences for costs and effects over time. The age of the 
patients was varied between 25-97 years for THR patients and 23-97 years for 
HFS patients (6).  The percentage of patients that require a nurse visit after 
discharge to administer fondaparinux was varied between 0% and 100%. The 
impact of length of stay (LOS) on the results was analysed by varying LOS after 
HFS from 4-28 days, and after THR from 5-30 days, respectively. These ranges 
were obtained from the APDRG data (26). The values correspond to the upper 
and lower bounds for the length of stay when outliers are excluded.  
 
Results  
Given the results of the model, providing extended prophylaxis with 
fondaparinux to HFS patients avoids 9 DVTs, 5 non-fatal PEs and 10 fatal PEs per 
1000 patients treated when a time horizon of 30 days is used. The incremental 
cost effectiveness ratio (ICER) at day 30 in these patients was CHF 2801 per LYG. 
Since the risk of a VTE is lower in THR patients, extended prophylaxis with 
fondaparinux avoids 16 DVTs, 5 non-fatal PEs, and one fatal PE per 1000 patients 
when a time horizon of 30 days is used. This translates into an ICER of CHF 
20’294 per LYG. 
In the analysis using a time horizon of 30 days, an estimated 135 of the 
1000 THR patients and 346 of the 1000 HFS patients receiving a one-week 
fondaparinux regimen will have experienced a VTE, as opposed to 11 out of 1000 
THR patients and 21 out of 1000 HFS patients in the extended prophylaxis arm. 
Looking at PE events only, at day 30 the event rate  for HFS and THR patients is 
21 out of 1000 and 8 out of 1000, respectively. Extended prophylaxis reduces 
these rates to 6 per 1000 for HFS patients and 1.9 per 1000 for THR patients. 
After 5 years, extended fondaparinux prophylaxis is cost saving compared to the 
one-week regimen for both HFS and THR patients.  
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Sensitivity analysis 
Table 3 shows the results of the sensitivity analysis on costs. The ICER is 
most sensitive to the daily cost of fondaparinux as shown in the corresponding 
tornado diagrams (Figure 1 and 2). The two next most influential variables are the 
cost associated with PE treatment after hospital discharge and the cost for DVT 
treatment after hospital discharge in HFS patients. Other cost parameters do not 
have a major impact on the results (The ICER varies by less than CHF 250). 
Figure 2 shows the tornado diagram for costs in THR patients. The sensitivity of 
the ICER to variations in cost parameters are similar to HFS patients. 
Importantly, after 5 years, the results are robust to any substantial variations in 
model cost parameters and usually result in cost-savings. 
A sensitivity analysis was also performed on major clinical model 
parameters as shown in Table 4. In HFS patients, the results were stable to 
variations in clinical model parameters at day 30 and after 5 years. However, in 
THR patients, the age of the patients has a substantial impact on the ICER. The 
ICER may vary between CHF 18’727 and CHF 125’353 per LYG at day 30. 
However, when a time horizon of 5 years is used, the results become stable to 
variations in age.  
 
Discussion 
In this paper we show that extending fondaparinux prophylaxis in major 
orthopaedic surgery from one week to four weeks may result in cost-savings after 
five years.  When a shorter time horizon of 30 days is used, extended 
fondaparinux thromboprophylaxis costs CHF 2'801 per life year gained in HFS 
patients, and CHF 20'294 per life year gained in THR patients.  
We used a time horizon of five years in our main analysis. The time horizon 
of the analysis should be long enough to reflect important differences between the 
long-run consequences and costs of alternative treatment options and strategies 
(31). A shorter time horizon of 30 days does not capture events that would occur 
after the initial four weeks of prophylaxis and underestimates the cost-
effectiveness of the intervention. A time horizon of 5 years was chosen as a longer  
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Table 3. Results of the sensitivity analysis on costs for the two patient groups and at different points in time (ICER = incremental 
cost-effectiveness ratio; HFS = hip fracture surgery; THR = total hip replacement; LYG = life year gained; DVT = deep vein thrombosis; PE = 
pulmonary embolism; BI = bleeding index; PTS = post thrombotic syndrome).  
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Table 4. Sensitivity analysis on other major model parameters (ICER=incremental cost-effectiveness ratio; HFS=hip fracture surgery; 
THR=total hip replacement; LYG=life year gained; PE=pulmonary embolism; RR=relative risk; LOS=length of stay). 
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Figure 1. Sensitivity analysis on costs for HFS patients 
Arixtra=cost of fondaparinux; PE=pulmonary embolism; dis.=discharge; DVT=deep vein thrombosis; bleeding=bleeding with bleeding index ≥ 2; 
susp=suspected 
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Figure 2. Sensitivity analysis on costs for THR patients 
 Arixtra=cost of fondaparinux; DVT=deep vein thrombosis; PE=pulmonary embolism; dis.=discharge; DVT=deep vein thrombosis; 
bleeding=bleeding with bleeding index ≥ 2; susp=suspected 
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time horizon better reflects the full value of this regimen in terms of complications 
and costs prevented.  
As was also shown for enoxaparin, extending thromboprophylactic prophylaxis 
from one week to four weeks is likely to be cost-effective (32;33). In the study by 
Bergqvist et al. (32), based on a Swedish trial (34), extended prophylaxis with a low-
molecular-weight-heparin (enoxaparin) was cost-saving under reasonable 
assumptions. In this trial, patients were hospitalised for 9 - 11 days and then received 
extended enoxaparin prophylaxis or placebo for another 19 - 23 days. Patients that 
received extended prophylaxis had significantly less VTE (most of which were 
asymptomatic). In addition, there was a significant reduction in the incidence of 
symptomatic thromboembolic events (34). Although extended enoxaparin was found 
to be cost-effective within this 4-week time horizon, important clinical benefits may 
have been omitted from the analysis by using a time horizon that is too short to 
capture the full clinical benefit of the extended prophylaxis regimen.   
The substantial clinical benefit of extending thromboprophylaxis with 
fondaparinux from one week to four weeks translates into cost savings after five 
years. However, whether extended prophylaxis with fondaparinux compared to an 
extended enoxaparin regimen is cost-effective would need to be evaluated in an 
additional study. More evidence on the effectiveness and cost-effectiveness of 
extended fondaparinux treatment compared to enoxaparin would ideally be derived 
from a head-to-head randomised trial that is not yet available to date. However, the 
results of such a clinical trial would still need to be further evaluated within a 
modeling study to capture the long-term benefits of extended thromboembolic 
prophylaxis.  
The treatment effect of extended fondaparinux prophylaxis was derived from 
the Penthifra Plus trial. This trial uses the same outcome measure as the Penthifra 
trial (5) whose results have been questioned since surrogate end points 
(venographically detected DVT) were used (35). However, asymptomatic, distal DVT 
is argued to be probably the only causal pathway that leads to proximal DVT and 
pulmonary embolism (36). In meta-analyses conducted on low-molecular-weight-
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heparin administered to patients undergoing elective joint replacement surgery, it 
could be shown that a reduction of venographically detected DVT was associated with 
a proportional reduction in symptomatic VTE (9;37;38).   
We used life years gained as the main outcome measure in our cost-
effectiveness analysis. This allows decision makers to compare the results of this 
study with the results of other studies that have been conducted on other health 
technologies that mainly address survival. Preventing thromboembolic events that do 
not necessarily lead to death also results in gains in quality of life. Adjusting length of 
life for quality of life (i.e., quality-adjusted life-years) would have been an alternative 
outcome measure that would have also captured the benefit of extended prophylaxis 
with respect to the patient’s quality of life. However, quality of life data were not 
available for this study. Our analysis therefore underestimates the cost-effectiveness 
of fondaparinux prophylaxis after 30 days and can be seen as a conservative estimate 
of the incremental cost-effectiveness ratio.  
The age and life-expectancy of the patients may substantially affect the cost-
effectiveness of the intervention. Preventing the death of a young patient will result in 
more life years gained than preventing the death of an older patient with a lower life 
expectancy. In our model the mean age of the population modelled was 65 years for 
THR patients and 76.6 years for HFS patients. These values have been derived from 
the four trials that were mainly used as a source for the model input parameters 
(5;6;10;11). In a sensitivity analysis the age of the patient substantially influenced the 
cost-effectiveness of extended fondaparinux prophylaxis after 30 days. However, 
using a five-year time-horizon, extended prophylaxis still results in cost-savings.   
In the model it was assumed that eight percent of the extended prophylaxis 
patients would need to be cared of by a nurse in order to have fondaparinux injected 
after hospital discharge. This estimate was based on a published study by Spahn (39). 
Of the 207 patients who underwent knee arthroscopy, 8% rejected to self-inject a low-
molecular-weight-heparin (LMWH). This estimate might be larger in other patient 
populations and settings. In a study by Harrison and colleagues (40) only 70% of 
patients felt comfortable with the self-injection of a LMWH. However, when we 
assumed that none of the patients would be able to self-inject fondaparinux in the 
sensitivity analysis, extended prophylaxis still resulted in cost savings in HFS patients 
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after 5 years and yielded a moderate incremental cost-effectiveness ratio for THR 
patients.  
The results after 5 years depend on the inclusion of PTS into the analysis. In 
general PTS has not been well characterized and different definitions of PTS exist 
(2;41). 
The uncertainty of including PTS into the analysis has partly been addressed 
by the sensitivity analysis on PTS costs (Table 3). The range of values used for the 
costs of treatment of acute PTS did not have any impact on the ICER after 5 years. 
The sensitivity analysis on costs for chronic PTS treatment showed only a marginal 
impact on the ICER.  
 
Finally, the drug price of fondaparinux treatment influences the incremental 
cost-effectiveness ratio most. For the base case analysis, the daily cost of 
fondaparinux prophylaxis was based on the Swiss Drug Compendium 2004. The 
incremental cost-effectiveness ratios were recalculated in a sensitivity analysis when 
the drug price was lowered or increased by 20%. But even with 20% higher drug 
costs, extended fondaparinux VTE prophylaxis would result in cost savings after 5 
years. On the other hand, health care providers that may eventually benefit from 
discounts when pharmaceuticals are purchased in large quantities (bulk discounts), 
would experience lower initial costs, resulting in even more favourable results for the 
cost-effectiveness of extended fondaparinux prophylaxis four weeks after orthopaedic 
surgery. 
In conclusion, our results suggest that extending thromboprophylaxis with 
fondaparinux from one week to four weeks in patients undergoing hip fracture 
surgery and total hip replacement in Switzerland is likely to be cost-effective after 30 
days and cost-saving after 5 years.  
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Expert opinion 
In this study based on a decision analytic model it was shown that extending 
thromboprophylaxis from one week to four weeks is cost-effective in patients 
undergoing hip fracture surgery and total hip replacement. For a treatment to be 
cost-effective, clinical effectiveness is a prerequisite. The estimates of the increased 
effectiveness of extended fondaparinux treatment were derived from the Penthifra 
Plus study (6). Other input parameters were derived from published studies and the 
robustness of the model was evaluated in extensive one-way sensitivity analyses.  
At the moment there is no accepted threshold value that defines the cut-off 
point between cost-effective and cost-ineffective treatments in Switzerland. The 
estimates of the cost-effectiveness for the prophylactic treatment with fondaparinux 
both in hip fracture surgery patients and total hip replacement surgery patients lie 
well below the frequently quoted 30’000 UK pounds per (quality adjusted) life year 
that are used in many cost-effectiveness studies (42;43). Assuming that the 
willingness to pay per unit of outcome is at least as high in Switzerland as it is in the 
UK, it can be concluded that extended thromboprophylaxis in those patients is cost-
effective. Incorporating the full clinical benefit into the analysis by increasing the 
time horizon to five years shows that extended fondaparinux thromboprophylaxis is 
cost-saving.  
 
Five-year view 
The routine use of fondaparinux for thromboprophylaxis in hip fracture 
surgery patients is now recommended in the latest guidelines of the American College 
of Chest Physicians (44). The quality of the evidence that led to this recommendation 
is rated as being of grade 1A. The recommended duration of prophylaxis is a 
minimum of 10 days and 28 to 35 days for those patients who are considered to be at 
high risk for VTEs (grade 1A)(44).  
Given the results of the Penthifra Plus trial (6) the use of extended 
thromboprophylaxis with fondaparinux in THR and HFS patients will increase. In 
order to ensure that all patients will receive appropriate care the prophylactic 
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regimens have to be standardized (45). This will also include a routine assessment of 
risk factors that will make it possible at least to provide extended prophylaxis to those 
patients that are at high risk of a VTE (46).  
 
Key issues 
• Patients undergoing major orthopaedic procedures (hip fracture surgery, total hip 
replacement) are at increased risk of developing venous thromboembolic events 
• The most common complications in these patients are the deep vein thrombosis 
which can cause pulmonary embolism (mortality 0.2%) or the post-thrombotic 
syndrome   
• Effective prophylactic agents exist and are routinely used (warfarin, LMWH, 
fondaparinux) 
• The effectiveness of fondaparinux has been shown in the Penthifra trial; extending 
the treatment duration from one week to four weeks further improves the 
prophylactic potency of fondaparinux (Penthifra Plus trial) 
• This cost-effectiveness analysis that is based on a decision analytic model shows 
that extending the treatment duration from one week to four weeks is cost-
effective for both patient groups, using a longer time horizon of five years extended 
prophylaxis with fondaparinux becomes cost-saving 
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CHAPTER 3: RISEDRONATE 
 
Cost-effectiveness of risedronate treatment for preventing 
osteoporotic fractures in Swiss postmenopausal women 
Abstract 
 
Objective: Osteoporosis is a major public health concern in Switzerland and is 
associated with an increased rate of bone factures, health care costs, mortality and 
loss of quality of life. Risedronate has been shown to effectively prevent fractures in 
patients with osteoporosis. We examined the cost-effectiveness of risedronate from 
the Swiss health care perspective for the treatment of osteoporosis in elderly 
postmenopausal women.  
Methods: A probabilistic Markov model was developed to address this issue. Data for 
the treatment effect was derived from a meta-analysis and quality of life estimates 
were extracted from a systematic review. Costs were identified by using Swiss sources 
and expressed in Swiss Francs (CHF) for the year 2007.  
Results: Osteoporotic women 70 years of age with a T-score of -2.5 who are treated 
over 5 consecutive years with risedronate and vitamin D and calcium, experienced on 
average 0.064 additional QALYs (95% CI: 0.040 QALYs to 0.090 QALYs) compared 
to patients treated with vitamin D and calcium alone. Costs in the treatment group 
were CHF 4516 higher (95% CI: CHF 3668 to CHF 5264), yielding an incremental 
cost-effectiveness ratio (ICER) of CHF 70323/QALY. For women 70 years of age with 
a T-score of ≤-2.5 SD the ICER is CHF 16475/QALY.  
Conclusions: Based on a decision analytic model the results of this study suggest that 
risedronate is cost-effective in the Swiss setting for the treatment of osteoporosis in 
70-year-old females at the threshold of osteoporosis or with established osteoporosis.  
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probabilistic sensitivity analysis  
Introduction 
Osteoporosis is a chronic disease which leads to low bone mass and increased bone 
fragility resulting in an increased risk of bone fractures. Osteoporosis is more than 
three times more common in postmenopausal women than in men and the risk of 
osteoporosis related fractures increases with age (1-3). The most common 
osteoporotic fractures are vertebral fractures, hip fractures and wrist fractures (1-3). 
Hip fractures are related to considerable morbidity and mortality (4-6) and reduced 
quality of life (7-9). As hip fractures generally require hospitalisation, surgery and 
subsequent rehabilitation,  treatment costs are high and osteoporosis induced costs to 
the health care system are substantial. For Switzerland alone total costs due to 
osteoporosis and related fractures were estimated to be CHF 357 millions for the year 
2000 (1). It was further estimated that total fracture-related first-year inpatient costs 
will rise by 31.5% to CHF 584 millions by the year 2020 (10). With rising expenditure 
on health care and limited budgets the value for money of interventions becomes 
increasingly important.   
Pharmacologic treatment against osteoporosis consist of antiresorptive and anabolic 
agents that are combined with calcium and vitamin D (11; 12).  Antiresorptive agents 
reduce bone remodelling and comprise bisphosphonates like risedronate, raloxifene a 
selective estrogen-receptor modulator, calcitonin and strontium ranelate. 
Bisphosphonates are the most commonly used agents today in the treatment of 
postmenopausal osteoporosis. In the US, risedronate is used in about 22% of patients 
receiving bisphosphonate (13). Several large clinical trials (14-17) and meta-analyses 
of randomised controlled trials (18-21) have shown that risedronate reduces vertebral 
and non-vertebral fractures in postmenopausal women with established osteoporosis.  
Data on the  cost-effectiveness of risedronate for the Swiss setting are sparse. (22). 
Our study provides an economic evaluation of the cost-effectiveness of risedronate 
treatment (with calcium and vitamin D) compared to calcium and vitamin D intake 
alone in postmenopausal women with established osteoporosis in Switzerland from a 
third party payer perspective. Our cost-utility analysis is based on a decision analytic 
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model that allows to project the course of the disease and the corresponding costs 
over time.  
Methods 
 
The Model 
We constructed a half-cycle corrected Markov model with Microsoft Excel and 
Microsoft Visual Basic 6.5 (Microsoft Corporation, Redmond, WA, USA). The model 
structure is based on a previously published reference model [Figure 1](23). We 
modelled a cohort of patients either receiving risedronate plus calcium and vitamin D 
or a basic treatment with calcium and vitamin D. The cohort was assumed to start in 
the well health state in cycle zero and face the monthly risk of experiencing a hip, 
wrist, vertebral or humerus fracture (cycle length = 1 month) and consequently move 
to one of the corresponding fracture specific health states.  
 Throughout the model patients are at an age specific risk of dying from a 
natural death (24). For the base case analysis the age of the cohort at treatment 
initiation is 70 years. The time horizon of the analysis is the patients’ remaining 
lifetime.  
 
Figure 1. State transition diagram. Transitions to the death state not shown.  
Legend:  fx = fracture;  vert = vertebral 
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Disease risk 
Swiss fracture incidences for the four fracture sites were calculated from Swiss data 
for 10 age groups – each comprising 5 years – for the ages 50 years to 100 years. This 
was achieved by matching the number of cases with the number of women at risk for 
experiencing a fracture. The number of cases of the year 2005 (cases identified by 
ICD-10 code) per fracture site were obtained from the Medical Statistics of Hospitals, 
published by the Swiss Federal Statistical Office (24). Swiss age and gender specific 
population statistics data for the year 2005 was obtained from the same source. The 
quality of the Swiss Federal Statistical Office  data is good – on average 98% of all 
cases are being recorded in the Medical Statistics of Hospitals (24). As not all 
fractures can be attributed to osteoporosis - it is estimated that only 91% of all hip 
fractures in 75-84 year old women can be attributed to osteoporosis  - we  adjusted 
the osteoporosis related fracture incidences accordingly with osteoporosis attribution 
rates published for Switzerland (1). All incidences (annual rates) were then 
transformed into monthly probabilities (25)[Table 1]. 
 To account for the increased fracture risk in osteoporotic women with a T-
score of either -2.5 SD or ≤-2.5 SD, baseline fracture incidences were adjusted using 
data published by Kanis et al. (26)[Table 2]. It should be noted, that based on the 
study by Kanis et al.  osteoporotic women of any age with a T-score of ≤-2.5 SD have 
at least a 40% increased fracture risk at any  site. In contrast, the relative risk of a 
fracture at the fracture sites under analysis decreases for women with a T-score of -
2.5 SD and aged 80 years or older relative to the population at risk (26).     
 
Increased mortality and increased fracture rates 
Women who experience a hip or vertebral fracture are at increased risk of dying 
subsequent to the fracture or in the following year. Swiss age, gender and fracture 
specific data was used in the model to account for the increased mortality after hip 
and vertebral fractures (6; 22). Likewise, women with a prior fracture have an 
increased risk of any subsequent fracture. In the model we applied fracture site, age 
and gender specific relative risk data - obtained from a meta-analysis - to account for 
the difference in risk between women with or without a prior fracture (27).    
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T-score -2.5 SD 
       Hip                 Vert                         Wrist                     Humerus Distribution 
Age Mean SD Mean SD Mean SD Mean SD  
60-64 0.0001385 0.0000088 0.0000783 0.0000052 0.0003646 0.0000112 0.0001466 0.0000055 beta 
65-69 0.0002184 0.0000116 0.0001149 0.0000071 0.0004008 0.0000126 0.0001699 0.0000066 beta 
70-74 0.0003470 0.0000135 0.0001429 0.0000076 0.0004236 0.0000127 0.0001796 0.0000066 beta 
75-79 0.0007383 0.0000208 0.0002692 0.0000112 0.0004761 0.0000138 0.0002625 0.0000094 beta 
80-84 0.0011305 0.0000250 0.0004068 0.0000141 0.0004719 0.0000144 0.0002599 0.0000098 beta 
85-89 0.0013466 0.0000314 0.0004774 0.0000187 0.0004661 0.0000177 0.0002566 0.0000120 beta 
90-95 0.0015069 0.0000417 0.0004579 0.0000242 0.0003877 0.0000217 0.0002144 0.0000148 beta 
95+ 0.0015463 0.0000765 0.0003547 0.0000386 0.0002840 0.0000337 0.0001587 0.0000231 beta 
 
Table 1A. Monthly fracture probabilities for women with a T-score of -2.5 SD. Mean values and standard deviations for different age 
groups and fracture sites. SD = standard deviation 
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Table 1B. Monthly fracture probabilities for women with a T-score of ≤-2.5 SD. Mean values and standard deviations for different age 
groups and fracture sites. SD = standard deviation 
 
 
T-score <-2.5 SD 
   Hip          Vert     Wrist                  Humerus Distribution 
Age Mean SD Mean SD Mean SD Mean SD  
60-64 0.0002481 0.0000157 0.0001400 0.0000093 0.0006532 0.0000200 0.0002626 0.0000099 beta 
65-69 0.0004212 0.0000224 0.0002222 0.0000137 0.0007752 0.0000243 0.0003285 0.0000127 beta 
70-74 0.0007209 0.0000281 0.0002968 0.0000159 0.0008832 0.0000265 0.0003744 0.0000138 beta 
75-79 0.0016163 0.0000456 0.0005959 0.0000249 0.0010509 0.0000305 0.0005793 0.0000207 beta 
80-84 0.0027473 0.0000608 0.0009903 0.0000344 0.0011441 0.0000349 0.0006302 0.0000237 beta 
85-89 0.0032645 0.0000760 0.0011603 0.0000453 0.0011361 0.0000430 0.0006255 0.0000292 beta 
90-95 0.0040571 0.0001123 0.0012347 0.0000652 0.0010475 0.0000587 0.0005792 0.0000399 beta 
95+ 0.0041631 0.0002059 0.0009564 0.0001042 0.0007673 0.0000911 0.0004289 0.0000623 beta 
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Age RR with T-score of -2.5 SD RR with T-score of <-2.5 SD 
 Vert Hip Wrist Vert Hip Wrist 
60  1.32 2.35 1.20 2.36 4.21 2.15 
65 1.21 1.82 1.06 2.34 3.51 2.05 
70 1.04 1.42 0.94 2.16 2.95 1.96 
75 0.89 1.11 0.82 1.97 2.43 1.81 
80 0.76 0.86 0.73 1.85 2.09 1.77 
85 0.65 0.66 0.64 1.58 1.6 1.56 
90 0.56 0.52 0.57 1.51 1.4 1.54 
 
Table 2. Increased fracture risk for ostoeporotic women, as published by Kanis et al. 
(26). RR = relative risk; SD = standard deviation 
Treatment effects  
We derived estimates for the treatment effects of risedronate from a meta-analysis of 
randomised placebo controlled trials (21) showing a reduced risk for fractures from 
all sites when compared to vitamine D and calcium: The relative risk (RR) was 0.63 
(95% CI, 0.51 to 0.78) for vertebral fractures, 0.60 (95% CI 0.42 to 0.88) for hip 
fractures, 0.67 (95% CI 0.50 to 0.90) for  humerus fractures, and  0.68 (95% CI 0.43 
to 1.08) for wrist fractures, respectively [Table 3].   
 For the base case analysis we assumed a treatment duration of 5 years with full 
adherence, followed by 5 years of offset time. During the offset time, we assumed that 
risedronate’s effectiveness declines linearly from full to no effectiveness.  
Quality of life data 
We use health state utility values as reported by Kanis et al. (28),  age and gender 
specific UK baseline quality of life (QoL) values from the literature (29) and data 
provided by Paul Kind (University of York, UK, personal communication) because no 
Swiss quality of life data of sufficient quality was available. However, baseline health  
Chapter 3: Risedronate 
64 
 
 
  
Parameter Mean SD Distribution Source 
Relative Risk     
RR hip 0.60 0.046 normal (21) 
RR wrist 0.68 0.092 normal (21) 
RR vert 0.63 0.107 normal (21) 
RR humerus 0.67 0.122 normal (21) 
     
Costs [CHF]     
hip fx 7232 2236 gamma (30) 
wrist fx 4336 830 gamma (30) 
vert fx 5456 1753 gamma (30) 
humerus fx 8505 2670 gamma (30) 
hip rehab 5508 1574 gamma (33; 63) 
wrist rehab 805 230 gamma (36; 63) 
vert rehab 1830 523 gamma (34; 63) 
humerus rehab 1647 471 gamma (35; 63) 
risedronate/month 62.75 - - (42) 
GP visit/year 315 - - (41) 
 
Table 3. Treatment efficacy and costs. SD = standard deviation; RR = relative risk; CHF 
= Swiss francs; fx = fracture; rehab = rehabilitation; GP = general practicioner 
 
related quality of life is likely to be similar in the Swiss and UK populations as 
indicated by estimates from the 2002 Swiss  Health Survey (24) that was based on 
telephone interviews.  
 To estimate age and health status specific quality of life values, the values of 
the general population were multiplied with the values for women with established 
osteoporosis for each health state. This assumes that the loss in quality of life due to 
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an event is dependent on the pre-event quality of life (e.g. younger people with higher 
pre-fracture QoL have more to loose)[Table 4].  
Parameter Age Mean SD Distribution Source 
well 60-64 0.81 0.26 beta (28) 
well 65-74 0.78 0.25 beta (28) 
well 75+ 0.71 0.27 beta (28) 
hip 60-64 0.65 0.22 beta (28) 
hip 65-74 0.62 0.22 beta (28) 
hip 75+ 0.56 0.23 beta (28) 
wrist 60-64 0.81 0.26 beta (28) 
wrist 65-74 0.78 0.25 beta (28) 
wrist 75+ 0.71 0.27 beta (28) 
humerus 60-64 0.74 0.24 beta (28) 
humerus 65-74 0.71 0.23 beta (28) 
humerus 75+ 0.65 0.25 beta (28) 
 
Table 4. Quality of life data. SD = standard deviation 
 
Cost data 
Costs for the treatment of fractures were obtained from the Swiss All Patient 
Diagnosis Related Groups (APDRG) version 5.1 (30)[Table 3]. For fractures where 
more than one diagnosis related group (DRG) was available (i.e. cases with and 
without complications) we combined the costs from all relevant DRGs weighted by 
the number of cases in 2005. As treatment costs in Switzerland differ between 
university and non-university hospitals, we weighted the different costs by the 
number of total cases treated in university and non-university hospitals. Fracture 
patients will require musculoskeletal rehabilitation after discharge from hospital (31-
33). Duration and intensity of rehabilitation was taken from the literature (33-37). 
Costs per physiotherapy sessions were estimated from the cost data for rehabilitation 
from the association of Swiss hospitals and rehabilitation clinics (38): hip fracture 
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CHF 12813, wrist fracture CHF 5141, vertebral fracture CHF 7286 and humerus 
fracture CHF 10152.   
 To account for complications in hip fracture surgery (e.g. bacterial infections, 
loosening of the prosthesis) we conservatively estimated in hospital treatment costs 
to increase by 1% (39; 40). 
 Patients in the post-hip and post-vertebral fracture health states are assumed 
to have impaired physical functioning and consequently are in need of home care 
(e.g. help with personal hygiene). Costs for this were obtained from Spitex, a large 
Swiss home care organization (Spitex, Basel, personal communication). Monthly 
home care costs were conservatively estimated at CHF 1314 [Table 3].   
 Patients under risedronate treatment will need at least one annual visit at their 
general practitioner. Costs for this visit are assumed to amount to CHF 315 (41). 
Monthly costs for risedronate were obtained from the Swiss Drug Compendium 
(42)[Table 3].  
 
Analysis 
The estimate of the cost-effectiveness of risedronate therapy compared to no therapy 
is presented as the incremental cost-effectiveness ratio (ICER; i.e. the ratio of 
incremental costs over incremental effects)(43) and as the incremental net monetary 
benefit statistics (44). We calculate the total health effect and obtain the 
corresponding resource use for each treatment strategy. The health effect is measured 
in quality adjusted life years to incorporate any differences in mortality and 
morbidity into the analysis (45). 
 All costs in the model are in Swiss Francs (CHF) of the financial year 2007. 
Costs and health effects are discounted with monthly compounding at an annual 
discount rate of 3%.  
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Sensitivity analysis 
Parameter uncertainty is addressed by probabilistic sensitivity analysis (PSA) with 
10 000 Monte Carlo simulations (46-48). Hence, parameters in the model are 
assigned individual probability distributions by the method of moments fitting (49). 
We used normal distributions for the RR parameters, gamma distributions for the 
cost parameters, and beta distributions for the quality of life and fracture incidence 
parameters. Uncertainty in all model parameters was based on the same source as for 
the mean values without any further assumptions.    
We explore with extensive one-way sensitivity analyses  the effect of different values 
for parameters that may vary but are not subject to parameter uncertainty and may 
therefore not naturally be ascribed a probability distribution (i.e., starting age, 
treatment duration, offset time and discount rate).  
 
Results 
Base case analysis 
Results for the base case analysis (women starting treatment at age 70) are shown in 
Tables 5 and 6. Females with postmenopausal osteoporosis, aged 70 years with  a T-
score of -2.5 SD, and 5 year consecutive treatment  with risedronate will experience 
8.686 QALYs (95% CI 7.205 QALYs to 9.939 QALYs) compared to 8.621 QALYs (95% 
CI 7.161 QALYs to 9.861 QALYs) experienced by individuals without risedronate 
treatment when assuming 100% drug adherence. The average total treatment costs 
under risedronate therapy are CHF 22 369 (95% CI CHF 19 935 to CHF 25 280) 
compared to CHF 17,952 (95% CI CHF 15 017 to CHF 21 284) for the no treatment 
strategy. This yields an incremental cost-effectiveness ratio of CHF 70,323 per QALY.   
 Women aged 70 years with a T-score of ≤-2.5 SD gain 0.121 QALYs compared 
to untreated women (95% CI 0.074 QALYs to 0.171 QALYs) [Tables 5 & 6]. Total costs 
are CHF 38 141 (95% CI CHF 32 913 to CHF 43 911) for women treated with 
risedronate  and CHF 36 139 (95% CI 30 096 QALYs to 42 857 QALYs) for women 
with no therapy. With incremental costs of CHF 2 001 (95% CI CHF 322 to CHF 3 
429) the ICER then is CHF 16 475/QALY.    
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Age at initiation of therapy 
The age of the patients at which the treatment is initiated has a large impact on the 
estimated cost-effectiveness of risedronate. Figure 4 shows the ICER when treatment 
for osteoporotic women with a T-score of -2.5 SD and ≤-2.5 SD is initiated at different 
ages. For both patient populations, the ICER decreases until a starting age of 80 
years. For women with a T-score of <-2.5 SD who start treatment at age 74 or later, 
risedronate treatment becomes cost-saving (i.e. more effective and less costly than no 
treatment).   
Treatment duration and length of offset time 
Using a shorter treatment duration of one year (and assuming an offset time of one 
year) the ICER is CHF 310 427/QALY for 70-year-old women with a T-score of -2.5 
SD (for women with a T-score ≤-2.5 SD: CHF 141 888/QALY). Extending the 
treatment duration to 10 years lowers the ICER to CHF 39 872/QALY for women 
with a T-score of -2.5 SD (CHF -333/QALY for women with a T-score of ≤-2.5 SD).  
 Assuming no treatment effect during the offset time increases the ICER to 
CHF 146 969/QALY for 70-year-old women with a T-score of -2.5 SD (women with a 
T-score ≤-2.5 SD: CHF 57 291/QALY). Extending the offset time to 10 years lowers 
the ICER to CHF 42 767/QALY (women with a T-score ≤-2.5 SD: CHF 1524/QALY).  
 
Time horizon and discount rates 
Using a shorter time horizon of increases the ICER for both patient population, as not 
all treatment benefits are captured in the analysis. Applying different discount rates 
to the analysis yields the expected results.    
 
Probabilistic sensitivity analysis and value of information analysis 
Probabilistic sensitivity analysis provides an estimate of the cost-effectiveness of 
risedronate for different willingness to pay values [Table 6, Figures 2 & 3]. The 
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applied threshold value is crucial in the decision whether risedronate is cost-effective 
or not.  At a threshold value of CHF 50 000/QALY the probability that risedronate is 
cost-effective for osteoporotic women with a T-score of -2.5 SD  is 7%, at the higher 
threshold value of CHF 100 000/QALY, however the corresponding probability is 
90%. The probability that risedronate is cost-effective is much larger and approaches 
100% for women with a T-score ≤-2.5 SD who are at the highest fracture  risk. 
Depending on the applied threshold value, the decision uncertainty varies 
from large to small values [Figure 2]. Decision uncertainty can be expressed as the 
expected value of perfect information (EVPI)[Figure 3]. For both patient populations 
EVPI reaches a maximum of more than CHF 350 per patient. In practice EVPI is 
negligible for women with a T-score of ≤-2.5 SD and a willingness to pay of at least 
CHF 50 000/QALY. For women with a T-score of -2.5 SD total EVPI per patient is 
CHF 30 at a decision maker’s willingness to pay of CHF 50 000/QALY and increases 
to CHF 60 per patient when a willingness to pay of CHF 100 000/QALY is assumed 
[Table 6].     
Discussion 
Based on a decision analytic model we analysed the cost-effectiveness of risedronate 
treatment in osteoporotic women in a Swiss setting. For a variety of scenarios we 
have shown that the treatment of osteoporosis with risedronate is cost-effective. The 
cost-effectiveness of risedronate is dramatically influenced by the age of patients at 
treatment initiation. Older patients are at higher risk for any of the modelled 
fractures (hip, wrist, vertebral and humerus fractures) and thus will have a larger 
treatment benefit at the same treatment costs. If we assume a constant relative risk 
reduction from risedronate over age, the treatment prevents more fractures when the 
treated population is older. Risedronate therefore is more likely to be cost-effective in 
older patient populations. This general finding is supported by various cost-
effectiveness analyses (26; 50-52).  
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Age Population Costs  comp. 
[CHF] 
Effects comp. 
[QALYs] 
Costs 
risedronate 
[CHF] 
Effects 
risedronate 
[QALYs] 
Incremental 
costs [CHF] 
Incremental 
effects [QALYs] 
ICER 
[CHF/QALY] 
70 -2.5 SD 
17952 (15017 
to 21284) 
8.621 (7.161 to 
9.861) 
22369 (19935 
to 25280) 
8.686 (7.205 to 
9.939) 
4516 (3668 to 
5264) 
0.064 (0.040 to 
0.090) 
70323 
70 <-2.5 SD 
36139 (30096 
to 42857) 
8.224 (6.862 to 
9.371) 
38141 (32913 
to 43911) 
8.346 (6.947 to 
9.525) 
2001 (322 to 
3429) 
0.121 (0.074 to 
0.171) 
16475 
 
Table 5. Base case results. Costs, effects and ICER (mean values and 95% confidence intervals). ICER = incremental cost-effectiveness ratio; 
comp. = comparator; CHF = Swiss francs; QALYs = quality adjusted life years; SD = standard deviation 
 
Age Population INMB [CHF] @ 
CHF 50000/QALY 
INMB [CHF] @ 
CHF 
100000/QALY 
P (INMB>0) @ 
CHF 50000/QALY 
P (INMB>0) @ 
CHF 
100000/QALY 
EVPI 
[CHF/patient] 
@ 50000/QALY 
EVPI 
[CHF/patient] @ 
100000/QALY 
70 -2.5 SD 
-1305 (-2942 to 
457) 
1906 (-903 to 
4857) 
0.069 0.904 30 60 
70 <-2.5 SD 
4072 (913 to 
7498) 
10146 (4772 to 
15901) 
0.995 1 2.2 0 
Table 6. Probabilistic sensitivity analysis. Incremental net benefit and expected value of perfect information (mean values and 95% 
 confidence intervals). INMB = incremental net monetary benefit; CHF = Swiss francs; P = probability; QALY = quality adjusted life year; 
EVPI = expected value of perfect information; SD = standard deviation 
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Figure 2. Cost-effectiveness acceptability curves (starting age 70 years). P = 
probability; CHF = Swiss francs; SD = standard deviation 
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Figure 3. Expected value of perfect information per patient (starting age 70 years). 
CHF = Swiss francs; SD = standard deviation 
 
 
Figure 4. Univariate sensitivity analysis on starting age. ICER = incremental cost-
effectiveness ratio; CHF = Swiss francs; QALY = quality adjusted life year; SD = standard 
deviation 
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 Although for Switzerland there is no official data on the decision makers’ 
willingness to pay value per quality adjusted life year, using a threshold level of CHF 
100 000/QALY risedronate treatment is cost-effective for postmenopausal 
osteoporotic women with a T-score of ≤-2.5 SD and an age of 58 years or older (data 
not shown). For women with a T-score of -2.5 SD risedronate treatment becomes 
cost-effective for women 68 years or older, assuming the same threshold value.    
 In a recently published review, Fleurence and colleagues (53) found in most 
analysed  studies from Denmark, USA, UK and Sweden)that bisphosphonates are 
unlikely to be cost-effective in women younger than 50 years of age. Bisphosphonate 
therapy is most cost-effective in women at 70 years of age or older. For the age group 
60 to 69 years the authors found uncertainty concerning the cost-effectiveness of 
bisphosphonate therapy. A cost-utility analysis for alendronate in 9 European 
countries reported incremental cost-effectiveness ratios of cost saving to € 46 
326/QALY (for Italy) depending on the country, women’s age at baseline, bone 
mineral density and status regarding  previous fractures (54). For Germany the 
estimate was € 33 079/QALY. These values correspond to estimates of the ICER of 
about CHF 89 000/QALY (Italy) and CHF 52 000/QALY (Germany) in 2007 Swiss 
francs. Compared to these two countries, our estimate of CHF 82 682/QALY for 69-
year-old women lies in between these values. This is in line with the findings by 
Ström et al. (54) who report a general pattern of smaller cost-effectiveness estimates 
for countries at higher latitude and larger ICERs for countries located further south. 
A reason for this may be the varying pattern of fracture incidences across different 
countries (54).    
Our study has several strengths such as the rigorous way we set up and populated our 
model with data. Using a previous published model structure, the results of our 
analysis are more easily comparable to other studies, although generalisability may 
still be limited since we applied our analysis to a Swiss setting. To date there exist 
only two other cost-utility analysis of a bisphosphonate that have been published for 
a Swiss setting (22; 41). Krieg et al. found that treating postmenopausal women with 
risedronate for 5 years is associated with an incremental cost-effectiveness ratio 
between CHF 77 276/QALY and CHF -15 098/QALY, depending on the age of women 
at treatment initiation (numbers shown for ages 65 to 75 years) and their fracture 
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risk. The study is difficult to assess since the presentation of model inputs and 
outputs is sparse. Schwenkglenks et al.’s study (41) analysed the cost-utility of a mass 
screening programme followed by 5 years of alendronate treatment. This approach is 
different to ours and the ICERs are not comparable, since with Schwenkglenks et al.’s 
screening approach, women with T-scores of -2.5 SD and ≤-2.5 SD would be 
identified and subsequently treated. Thus, patient populations with different fracture 
risks cannot be distinguished anymore.  
 One of the limitations of our analysis is, that we assumed full drug compliance 
throughout the 5 years treatment period. It is known that in actual practice, 
compliance with bisphosphonate treatment is suboptimal (55-57). Modelling the 
impact of less than full compliance in decision analytic models has been discussed 
previously, but ultimate recommendations for handling this issue are inconclusive 
(58; 59). Hence, we assumed full compliance and may thus underestimate the ICER, 
but we are in line with a variety of cost-effectiveness analyses published to date (23; 
26; 54; 60; 61) using the same approach.  
 Apart from the usual probabilistic sensitivity analysis, we calculated the 
expected value of perfect information (EVPI) for our base line scenarios for two 
willingness to pay values. Expected value of perfect information places a monetary 
value on the opportunity loss that will arise both in monetary units and health 
benefits foregone, when the wrong decision is adopted (62). For osteoporotic women 
with a T-score of ≤-2.5 SD the EVPI is at a threshold level of CHF 50 000/QALY very 
small and approaches zero for larger threshold values. This means that the decision 
uncertainty is too small, that further information (that could inform the decision of 
whether risedronate is cost-effective for 70-year-old women with a T-score of ≤-2.5 
SD) will be of any value. In contrast, EVPI for 70-year-old women with a T-score of -
2.5 SD is relatively large for potentially relevant threshold values between CHF 50 
000/QALY and CHF 100 000/QALY. Collecting new data could be cost-effective in 
order to be able to put this decision on a more sound evidence basis.  
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Conclusion 
The results of our study suggest that risedronate treatment for preventing 
osteoporotic fractures in Swiss postmenopausal women is cost-effective for women 
with a T-score of ≤-2.5 SD. Risedronate treatment is cost-effective for osteoporotic 
women with a T-score of -2.5 SD at age 70 years or older. For younger women 
risedronate may be cost-effective, depending on the decision maker’s willingness to 
pay value per QALY.  
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CHAPTER 4: COMPLIANCE IN OSTEOPOROSIS DECISION ANALYTIC MODEL 
How much bone for the buck? On the importance of addressing 
compliance issues in economic evaluations of bisphosphonates. 
Medical care usually entails careful consideration of benefits, risks and costs. 
Bisphosphonate therapy for the prevention and treatment of osteoporosis has 
significant benefits at moderate risks that come at costs that are somewhat higher 
than the price of a box of calcium tablets . Prescription rates from the US show the 
increased acceptance of bisphosphonate therapy. 97% of all osteoporosis patients will 
leave their physician’s practice with a prescription, 73% of which will be for a 
bisphosphonate. Recent economic evaluations of bisphosphonate therapy have shown 
that these antiresorptive drugs are cost-effective for certain patient populations .  
Is this really always the case? How cost-effective is a treatment that may not be 
taken but instead takes up space in the bathroom cabinet (where drugs shouldn’t be 
stored in the first place anyway)? Did we forget about compliance? It is known that 
compliance with bisphosphonate therapy is often suboptimal. The results of a recent 
analysis by McCombs and colleagues show that the mean unadjusted duration of 
continuous therapy is 245 days for bisphosphonates . Further, we know that high 
compliance with bisphosphonate therapy reduces the risk of a fracture by 16% . Or to 
put in another way: low compliance will reduce the effectiveness of the intervention 
and consequently its cost-effectiveness.  
The vast majority of all economic evaluations of bisphosphonate therapy (or of 
interventions for the prevention or treatment of osteoporosis in general) are studies 
that make use of decision-analytic models. Based on the results of a recent review on 
economic evaluations for the prevention and treatment of osteoporosis, published 
between 1980 and 2004, 41 out of 42 studies were model-based . This is not 
surprising. Osteoporosis is a chronic disease, the event rate (fracture rate) is 
relatively small, and the beneficial effects of therapy will not be effective until months 
after the onset of therapy. Decision-analytic models like the frequently used Markov 
models provide the possibility of easily projecting the course of a chronic disease over 
time, including the respective number of events and resource use. However, because 
the model structure depends on the research question (and research group) and is 
naturally not predefined, it is up to the analyst to build a model in such a way that it 
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reflects clinical reality or the „real world.“ As compliance may substantially 
jeopardize effectiveness, this should clearly be taken into account when a decision 
analytic model is constructed .  
How has compliance been dealt with hitherto in published models? The 
striking result is: almost not at all, at least not explicitly. In a review of decision 
analytic modeling studies of the cost-effectiveness of interventions for the prevention 
of osteoporosis published in the years 2001 to 2004 (unpublished data, available on 
request from the authors), only 4 out of 17 studies addressed compliance issues either 
in the base-case analysis or in the sensitivity analysis. However, the majority of these 
studies addressed the problem of poor compliance in the discussion sections of the 
papers. Frequently, it was stated that poor compliance may influence the result of the 
analysis and would lower the effectiveness of the intervention. It was then further 
argued that such reduced effectiveness would „to some extent“ be offset by lower 
treatment costs . This sounds intuitively right, but we should be interested in total 
health care costs and not just treatment costs. A recent study by Sokol et al.  has 
shown that for four chronic conditions (diabetes, hypertension, hypercholesterolemia 
and congestive heart failure) compliance is negatively correlated not only with 
hospitalization risk, but also with total health care costs. So although medical costs 
may be lower because of poor compliance, overall health care costs might be larger. 
This is because of a larger hospitalization risk in patients that comply poorly with 
their therapy. However, McCombs and colleagues  do not find such a strong 
relationship between patient compliance with osteoporosis prevention/treatment and 
fracture risk. The additional drug costs of US$266 for one year, when the patient does 
fully comply with therapy, is only partly offset by the reduced costs for physicians (- 
US$56), hospital outpatient services (- US$38) and laboratory use (- US$9) and other 
hospital costs of - US$155 (total reduction of non-drug costs in case of compliance: 
US$258). But it should be noted that a higher fracture rate is also associated with 
productivity costs and a reduced quality of life. It is very likely that when the full 
societal economic consequences are considered, the impact of compliance on cost-
effectiveness would be even larger.  
But even if we exclude total health care costs from our analysis, there is 
something odd about stating that lower effectiveness through lower compliance is 
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partly offset by lower treatment costs. Why don’t we just simply say that we may 
overestimate the intervention’s cost-effectiveness (i.e., report too low incremental 
cost-effectiveness ratios) if compliance is suboptimal? The majority of researchers are 
aware of the problem of poor compliance. So why don’t we find more studies that 
properly deal with it? The answer to this can be found in a recent study on the cost-
effectiveness of the bisphosphonate alendronate, which stated that „compliance is not 
an easy issue to handle in economic evaluations“ .  
It is difficult to estimate the level of compliance with bisphosphonates over 
time and it is even more difficult to estimate the effect of poor compliance on the 
amount of relative risk reduction associated with bisphosphonate therapy. In order to 
be able to discuss the influence of poor compliance, we first need to establish what we 
mean by compliance or being compliant. One possible way that is frequent in the 
medical literature is to consider patients compliant if they have medication available 
during a certain duration of treatment time (e.g., prescriptions are obtained to cover 
80% of treatment time) . As we don’t know whether the patients are actually using 
the drugs they obtained, using this definition will overestimate the level of 
compliance, yielding a conservative estimate of patients‘ actual compliance. Some 
patients will have their tablets ready but then simply forget to take them or 
intentionally decide to stop taking their medication for whatever reason (e.g., side 
effects or costs of medication).  
In the end, it comes down to the question „how much compliance is sufficient 
for full effectiveness?“ This is determined by the drug‘s pharmacodynamics, i.e., the  
drug’s dose-response relation. There are drugs which require either substantially 
more or less than 80% of prescribed doses taken for full effectiveness. Although 
bisphosphonates have now been used for many years, their complex 
pharmacokinetic/pharmacodynamic relationship is not yet fully understood. Having 
said this, we should have a closer look at the data from McCombs et al.  again.  
McCombs et al. show that 42.7% of all patients in the first treatment year take 
their medication for less than 90 days and only 31% of all patients in their initial year 
of therapy have a level of compliance above 80%. These figures are based on 
prescription data of 3720 Californian patients who were prescribed bisphosphonates. 
In light of these data, it seems to be quite a strong assumption that a cohort of say 
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5000 patients would take their weekly (or even daily) dose of bisphosphonates for 5 
years without any interruption or break of therapy.                                                                                            
Another problem arises because we don‘t really know how patients do not 
comply. Some patients will just switch to other therapies, others will refuse to take 
any medication and a third group of patients will have an intermittent therapy that is 
just a little bit more intermittent than originally intended by the treating physician 
(i.e. they will forget to take their medication every now and then). One way to take 
these latter patients‘ lower compliance into account is to assume that a reduced level 
of compliance of for example 80% will result in only 80% of the drug’s full 
effectiveness (e.g., 80% compliance to a treatment with a relative (fracture) risk of 
0.6 under a level of compliance of 100% will result in an (increased) relative risk of 
0.68 (compliance adjusted relative risk = 1 – ([1-0.6]*0.8) = 0.68). Admittedly, 
assuming a linear relationship between relative risk reduction and compliance is 
fairly arbitrary, but the analyst may also want to explore alternative relationships in a 
sensitivity analysis if pharmacodynamic considerations do not clearly suggest how 
compliance and hence drug plasma levels may affect effectiveness.   
At the moment, we don’t have data to provide a standard prescription for how 
compliance should be technically dealt with in analyses, but neither do we think that 
omitting compliance issues from the analysis is the way to go. The absence of data is 
not in itself a justification for simplification .  Patients who switch therapies accrue no 
further costs and likewise obtain no further benefits if we do not assume the presence 
of any positive effect during the „offset time.“ This seems to be a reasonable 
assumption since 37% of bisphosphonate patients switch to a second medication 
within their initial treatment year, which is a short time period for any clinical effect 
to become significant and large enough to have an effect during the „offset time.“ 
Patients who just „store“ their medication at home probably do not make for the 
largest part of patients.  
In the end, what we have tried to emphasize in this editorial is that compliance 
may have a substantial impact on how much bone we get for the buck, and we 
therefore recommend its formal implementation in economic evaluations of 
bisphosphonates. 
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CHAPTER 5: DRUG-ELUTING STENTS 
 
Cost-Effectiveness of Drug-eluting Stents in a US Setting: A Cost-Utility 
Analysis with 3 Year Clinical Follow-up Data  
 
Abstract 
 
Background: The cost-effectiveness of drug-eluting compared to bare metal stents 
over a time horizon of more than one year is unknown. 
Methods: We developed a Markov model based on clinical outcome data from a meta-
analysis including 17 randomized controlled trials (RCTs) comparing drug-eluting 
versus bare metal stents with a minimum follow-up of one (n = 8221) and a 
maximum follow-up of 3 years (n = 4105) in patients with chronic coronary artery 
disease. Costs were obtained as reimbursement rates for diagnosis related groups 
(DRGs) from the US Centers for Medicare and Medicaid Services. All costs and effects 
were discounted at 3% annually. All costs are reported in US dollars of the financial 
year 2007.  
Results: The incremental effects are 0.001 (95% CI -0.032 to 0.038) QALYs for the 
sirolimus-, and -0.002 (95% CI -0.049 to 0.047) QALYs for the paclitaxel-eluting 
stents. The incremental costs are $1953 for the sirolimus- and $4329 for the 
paclitaxel-eluting stents. The incremental cost-effectiveness ratio is > $1 000 000 per 
quality adjusted life year for the sirolimus-eluting stent. The paclitaxel-eluting stent 
is dominated by bare metal stents (i.e. less effective and more costly). Among various 
sensitivity analyses performed, the model proved to be robust. 
Conclusions: Our analysis from a US Medicare perspective suggests that DES are not 
cost-effective compared to BMS when implanted in unselected patients with 
symptomatic ischemic coronary artery disease. 
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Introduction 
The economic burden of cardiovascular disease is substantial. In the year 2006, 
health care spending and lost productivity from cardiovascular disease exceeded 
$400 billion in the US (1). Among patients with coronary artery disease, stent 
implantation has become the treatment of choice in the last decade (2; 3). Currently, 
nearly 80% of all inserted stents in the US are drug-eluting stents (DES) (4). It is 
estimated that the world market for DES sums up to $6 billion annually (5).  
 In recently published meta-analyses of randomized controlled trials (RCTs) 
comparing bare metal to drug-eluting stents, drug-eluting stents were found to 
reduce restenoses and the need for revascularization procedures, but not overall 
mortality or the incidence of myocardial infarction (6-12).  
 As with many new interventions, there is a significant price premium on drug-
eluting stents when compared to conventional bare metal stents (BMS). Limited 
health care budgets increase the incentive to not only look at the clinical effectiveness 
of an intervention but also to take into account the cost-effectiveness of a novel 
therapy.  
 Several economic evaluations of DES exist to date, some of which are directly 
based on clinical trials and others on model-based economic evaluations (9; 13-18). 
However, there still remains a considerable controversy about the cost-effectiveness 
of DES when compared to BMS for all patients undergoing percutaneous coronary 
interventions (19; 20).  
 In a recent systematic review, Lightart and colleagues identified 19 cost-
effectiveness studies of DES that were published between January 2000 and July 
2006 (5). In their conclusions 10 studies were in favour whereas 9 studies were not in 
favour of widespread use of DES. Five of the 19 studies were performed from a US 
third party payer perspective, and favoured the widespread use of DES (21-25). All 
studies from the US used a short time horizon with maximum clinical follow-up of 
one year, and thus disregarded potential differences in other patient-relevant 
outcomes as well as quality of life estimates that may arise beyond the first year after 
stent implantation. Other studies used a single trial as a vehicle for the economic 
evaluation which will often lead to a partial and limited analysis (26).  
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 To provide a more thorough answer to the question whether the routine use of 
DES is cost-effective for the treatment of coronary artery disease from a US Medicare 
payer’s perspective, we developed a decision analytic model based on recently 
published data of long-term outcomes of randomized controlled trials comparing 
DES to BMS. We developed a model that allows for a probabilistic sensitivity analysis 
to address the joint implications of parameter uncertainty (i.e. uncertainty about the 
input data) on the uncertainty relating to the decision whether a novel technology is 
cost-effective (26).  
  
Methods 
 
A half-cycle corrected Markov cohort simulation model with the 5 mutually exclusive 
health states stent, non-fatal myocardial infarction (MI), percutaneous coronary 
intervention (PCI), coronary artery bypass graft surgery (CABG), and death was 
developed (Figure 1) (27). We compared two strategies: SES versus BMS and PES 
versus BMS. The transition probabilities from the index procedure to death, non-fatal 
myocardial infarction, clinically driven percutaneous coronary intervention, and 
coronary artery bypass grafting were derived from an updated, previously published 
meta-analysis of randomized controlled trials comparing SES or PES to BMS in 
patients with coronary artery disease  (11). Briefly, trials were required to report 
mortality data after at least one year of follow-up. Trials exclusively including 
patients with acute coronary syndromes or trials focussing on interventions in non-
native coronary arteries were excluded since these trials evaluate a different patient 
population. We conducted a systematic literature search of Medline, Embase, Web of 
Science, the Cochrane Library, websites dedicated to the dissemination of results 
from cardiovascular trials from January 1980 up to April 2006 and contacted the 
manufacturers of SES and PES. We identified 17 trials including 8221 patients that 
fulfilled inclusion criteria. Seven trials used SES (n=2487), 9 trials (n=4908) PES, 
and one trial (15) used (n=826) both DES. Twelve trials including 4631 patients 
reported outcome data after 2 years, 9 trials including 4105 patients reported 
outcome data after 3 years. Details on the selection process for potentially eligible 
trials, the characteristics and quality of included trials and on the generation of 
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summary estimates are provided in the appendix and have been published elsewhere 
(11). 
The cycle length in the model is one month to allow for a precise estimation of the 
timing of events and related cost. The study’s perspective is a US Medicare payer’s 
perspective. Estimates for all parameters where there was no data available from our 
meta-analysis were derived from a systematic search of the medical literature. All 
costs and effects were discounted at 3% annually using monthly compounding.  
 
 
 
 
 
 
 
 
 
 
Clinical parameters 
Transition probabilities are of central importance in a Markov model. The transition 
probabilities from the stent state to the health states MI, PCI, CABG and death were 
obtained by transforming point estimates for event rates and their corresponding 
standard deviations into monthly probabilities (for 0 to 30 days after the index 
procedure, for 30 days to one year, for year 1 to 2 and for year 2 to 3; for details see 
appendix [tables 1A, 1B and 2]) (27). PCI was defined as any percutaneous target 
vessel revascularization. From the meta-analysis, outcome data were available for the 
time period 30 days following the initial stenting procedure, and for the years 1, 2, 
and 3 after the index procedure. Likewise we obtained values for the relative risks for 
the same transitions. We used the method of moments fitting (28) to fit beta 
distributions to the transition probabilities derived from the meta-analysis, and fitted 
lognormal distributions to all relative risk parameters in the model. The remaining 
transition probabilities were taken from published studies (29-34) and are provided 
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in Table 1. We assumed that the transition probabilities from the PCI-state to the 
health states MI, CABG and death were the same as for patients in the “stent” state.  
 
Costs 
All costs in the model were obtained as reimbursement rates for diagnosis related 
groups (DRGs) from the US Centers for Medicare and Medicaid Services (35). We 
used reimbursement rates for the DRGs 121 and 122 (circulatory disorders with acute 
myocardial infarction with/without major complications discharged alive), 547-550 
(coronary bypass with/without cardiac catheterization with/without major CV DX), 
556 (PCI with non-DES without CV DX), and 557 and 558 (PCI with DES 
with/without major CV DX). Reimbursement rates for DES are independent of the 
type of DES used. For events where more than one diagnosis related group (DRG) 
was available (i.e. cases with and without complications) we combined the costs from 
all relevant DRGs weighted by the number of cases in 2006 (35). We assumed that 
physician fees would account for the same percentage share per event as reported by 
Mahoney et al. (36). For our base case we used average Medicare reimbursement 
rates of 10 top-rated cardiology hospitals in the United States (37), in a sensitivity 
analysis we used average reimbursement rates from a random sample of 10 US 
hospitals from the same source (35). Costs are provided in Table 1. We assumed that 
there would be no difference in resource use for antiplatelet medication because 
clopidogrel or ticlopidine were used for the same time period in patients treated with 
DES and BMS in all trials of the meta-analysis. Thus, costs for medications and 
follow-up visits were not included into the model.  
We fitted gamma distributions to reflect parameter uncertainty of the unit costs of 
the procedures. All costs are reported in US dollars of the financial year 2007.  
 
Outcomes 
The outcome of the two strategies was measured in natural units and quality adjusted 
life years (QALYs). This generic instrument weighs the length of life by the quality of 
life a patient has while being in a specific health state. QALYs combine both, 
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Table 1. Model parameters 
*Transition probabilities are shown as monthly probabilities  
†standard deviation 
‡nonfatal myocardial infarctions 
§coronary artery bypass graft 
║percutaneous coronary intervention 
 
 
 
 
 
Parameter Mean (SD) 
base case† 
Dist. Source Mean 
(SD) 
Source 
SA 
Transition probabilities* 
MI -> death (30 days)‡ 0.13 - (30) - - 
MI -> death (after 30 days)‡ 0.00569 - (30) - - 
CABG -> death (30 days)§ 0.015 - (36) - - 
CABG -> death (after 30 
days)§ 0.00255 - (36) - - 
CABG -> MI (first 30 days)§ 0.0276 - (32) - - 
CABG -> MI (after 30 days)§ 0.00077218 - (32) - - 
Disutilities [QALYs]      
MI‡ 0.0104 (0.00047) beta (3) 0.00658 (39) 
PCI║ 0.0104 (0.00047) beta (3) 0.00658 (39) 
CABG§ 0.0208 (0.00063) beta (3) 0.00658 (39) 
Costs [US dollars]      
PCI with BMS║ 18469 (3781) gamma (35) 14609 (2602) (35) 
PCI with DES║ 24536 (5042) gamma (35) 18429 (2910) (35) 
Acute MI‡ 15999 (3851) gamma (35) 11150 (1704) (35) 
CABG§ 51050 (10972) gamma (35) 37576 (5882) (35) 
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Table 1 continued 
Cost data for the base case represent average DRG reimbursement rates for 
the following 10 top-rated US hospitals: 
 
Cleveland Clinic, Cleveland, OH,   
Mayo Clinic, Rochester, MN  
Brigham and Women's Hospital, Boston, MA   
Massachusetts General Hospital, Boston, MA   
Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX   
Duke University Medical Center, Durham, NC   
Stanford Hospital and Clinics, Stanford, CA  
Barnes-Jewish Hospital/Washington University, St. Louis, MO   
UCLA Medical Center, Los Angeles, CA   
William Beaumont Hospital, Royal Oak, MI 
 
 
Cost data for the base case represent average DRG reimbursement rates for 
the following 10 randomly chosen US hospitals: 
 
 
Northern Michigan Hospital, Petoskey, MI         
Manchester Memorial Hospital, Manchester, CT         
Reynolds Memorial Hospital Inc., Glen Dale, WV        
Metrowest Medical Center, Natick, MA      
Saint Luke's Hospital of Kansas City, Kansas City, MO 
Whittier Hospital Medical Center, Whittier, CA 
Sumter Regional Hospital, Americus, GA 
St. Mary's Hospital, Centralia, IL 
Alexian Brothers Medical Center, Elk Grove Village, IL 
Madison County Hospital, London, OH 
 
 
 
 
 
morbidity and mortality into a single parameter and therefore allow comparing the 
effect of treatments across different disease areas. 
 We calculated QALYs using the approach by Bagust et al. (14). We assumed a 
baseline quality of life value of 0.86 for patients without an event. We estimated 
disutility values (i.e. a short term drop in patients’ quality of life) for patients with 
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PCI and CABG (Table 1) based on the results of the ARTS trial. In this trial quality of 
life values were obtained based on the EQ-5D questionnaire at baseline and 1, 6 and 
12 months after stenting or coronary artery bypass graft surgery for coronary artery 
disease (3). We calculated the disutility values by taking the difference in health 
related quality of life values between a patient with and without an event. Thus, the 
calculated disutility values reflect the loss in patients’ quality of life for up to 6 
months after the event. No loss in quality of life was assumed to occur 6 months after 
the event. For patients experiencing a myocardial infarction we attributed an ongoing 
disutility of 0.01 per month starting at the time of the event until end of follow-up 
based on a community-based study reporting self-perceived quality of life after 
myocardial infarction (38). In a sensitivity analysis we used disutility values per event 
as reported in a health technology assessment from the United Kingdom on the use of 
coronary artery stents (39) disregarding the patients’ loss in quality of life due to long 
waiting time (which generally does not apply to patients in a US Medicare setting).   
 
Analysis 
Total costs of the two strategies and the corresponding outcomes as number of 
quality adjusted life years experienced were recorded. The result of the analysis is 
expressed as the incremental net monetary benefit (INMB) for drug-eluting stents 
when compared to bare metal stents for 2 different threshold values ($50 000 and 
$100 000) (40). The INMB is calculated by the following standard equation:  
 
 INMB = ∆ effect * threshold value - ∆ costs 
 
INMB is therefore the difference in treatment effect of DES (incremental effect) 
multiplied by the willingness to pay (i.e. threshold value) per one unit of outcome 
gained (i.e. per QALY) minus the incremental (i.e. additional) net total health care 
costs for providing DES. By multiplying the incremental effect with the threshold 
value, the effect is transformed into a monetary unit. For the base case analysis, we 
assumed an arbitrary decision maker’s willingness to pay of $100 000 per QALY. A 
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positive INMB reflects that the intervention under analysis is cost-effective. The 
INMB approach yields the same results as when calculating the incremental cost-
effectiveness ratio. However, the INMB approach avoids the potential problem of 
averaging over positive and negative incremental effects and costs that may arise 
when performing a probabilistic sensitivity analysis with multiple iterations.  
 We performed a probabilistic sensitivity analysis with 5 000 Monte Carlo 
simulations (41; 42)  to account for parameter uncertainty that relates to the 
uncertainty in the analysis arising from the lack of definite knowledge about a 
parameter’s true value. We tested the robustness of the model towards model 
assumptions with univariate sensitivity analysis on estimates of clinical effectiveness, 
on different time horizons, on the difference of DRG reimbursement rates for BMS 
and DES, on health state utilities, on costs of PCI, MI and CABG, and on discount 
rates for costs and health effects. Since published data on the need for percutaneous 
coronary re-interventions report censored data after one event, but some patients 
have multiple interventions, we conducted an additional sensitivity analysis on the 
number of patients undergoing multiple percutaneous coronary reinterventions. 
Based on data from the BASKET trial (15), we assumed that there are about 5% more 
percutaneous interventions due to multiple interventions in individual patients. The 
model was developed with Microsoft Excel and Microsoft Visual Basic 6.5.  
 
Results 
In the comparison of SES to BMS, 23.09% of BMS patients require a repeat PCI, 
compared to 8.72% of SES patients. The incidence of MIs over the 3 year time 
horizon is 4.38% in BMS patients and 3.35% in SES patients. Likewise the incidence 
of CABG is lower in the DES group (BMS: 3.18%; SES: 2.19%). Mortality is slightly 
increased in SES patients (BMS: 2.62%; SES: 2.66%). Results for the PES to BMS 
comparison are similar (not shown), with the only marked difference being the 
smaller difference between the number of PCI events in the PES and BMS groups 
(14.95% in BMS versus 10.18% in PES patients). 
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Costs , effects, INMB and ICER* 
stent type† Costs [US$] Effects [QALYs]‡ 
Incremental 
costs [US$] 
Incremental 
effects [QALYs] 
INMB  [using 
$50 000 as 
threshold] 
INMB  [using 
$100 000 as 
threshold] 
ICER 
[US$/QALY] 
BMS 
 
SES 
26253 (24615 to 
28085) 
28206 (27513 to 
29014) 
2.358 (2.324 to 
2.378) 
2.359 (2.334 to 
2.376) 
 
 
1953 (-14 to 
3779) 
 
 
0.001 (-0.032 to 
0.038) 
 
 
-1914 (-4442 to 
795) 
 
 
-1875 (-5646 to 
2496) 
 
 
 1000000 
BMS 
 
PES 
24243 (23150 to 
25478) 
28571 (27851 to 
29409) 
2.362 (2.318 to 
2.385) 
2.360 (2.321 to 
2.383) 
 
 
4329 (2914 to 
5700) 
 
 
-0.002 (-0.049 to 
0.047) 
 
 
-4409 (-7102 to -
1654) 
 
 
-4490 (-7102 to -
1654) 
 
 
PES dominated 
 
 
Table 2. Costs , effects, INMB and ICER.  
*INMB=incremental net monetary benefit; ICER=incremental cost-effectiveness ratio; mean values and 95% confidence intervals, time horizon 3 
years 
†BMS=bare metal stent, SES=sirolimus-eluting stent, PES=paclitaxel-eluting stent 
‡QALYs=quality adjusted life years 
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Costs , effects, INMB and ICER, assuming no difference in event rates for deaths between BMS and DES* 
stent type† Costs [US$] Effects [QALYs]‡ 
Incremental 
costs [US$] 
Incremental 
effects [QALYs] 
INMB [using 
$50 000 as 
threshold] 
INMB [using 
$100 000 as 
threshold] 
ICER 
[US$/QALY] 
BMS 
 
SES 
26272 (24651 
to 28124) 
28203 (27510 
to 29020) 
2.356 (2.324 to 
2.376) 
2.359 (2.335 to 
2.376) 
 
 
1931 (-45 to 
3757) 
 
 
0.003 (-0.029 to 
0.039) 
 
 
-1785 (-4211 to 
843) 
 
 
-1640 (-5384 to 
2364) 
 
 
662581 
BMS 
 
PES 
24208 (23147 
to 25441) 
28569 (27865 
to 29415) 
2.360 (2.319 to 
2.384) 
2.361 (2.323 to 
2.384) 
 
 
4360 (2955 to 
5762) 
 
 
0.001 (-0.043 to 
0.047) 
 
 
-4324 (-7019 to 
-1554) 
 
 
-4289 (-9004 to 
650) 
 
 
 1000000 
 
Table 3. Costs , effects, INMB and ICER, assuming no difference in event rates for deaths between BMS and DES 
*INMB=incremental net monetary benefit; ICER=incremental cost-effectiveness ratio; mean values and 95% confidence intervals, time horizon 3 
years 
†BMS=bare metal stent, SES=sirolimus-eluting stent, PES=paclitaxel-eluting stent 
‡QALYs=quality adjusted life years 
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The incremental effects of the DES are 0.001 (95% CI -0.032 to 0.038) QALYs for 
SES and -0.002 (95% CI -0.049 to 0.047) QALYs for PES. The incremental costs are 
$1953 for SES and $4329 for PES. This yields an incremental cost-effectiveness ratio 
of > $1 000 000 for SES. PES are dominated by bare metal stents (i.e. PES less 
effective and more costly). Table 2 provides the expected costs and health effects for 
the base case analysis.  
The uncertainty for the decision is graphically represented on the cost-effectiveness 
plane [Figure 2]. Cost-effectiveness acceptability curves provide an estimate of the 
probability that DES are cost-effective for a range of different willingness to pay 
values [Figure 3]. At an arbitrary willingness to pay of $100 000 per QALY, SES have 
a 16% probability, and PES a 3.5% probability of being cost-effective.  
 
Univariate sensitivity analysis 
 In individual patient data meta-analyses comparing DES to BMS (6;8) there 
were no significant differences in the rates of death and myocardial infarction. Given 
the uncertainty around the point estimates of the relative risks for these outcomes in 
our meta-analysis, we conducted a sensitivity analysis assuming no difference in the 
number of deaths between patients treated with BMS and DES [Table 3]. Both DES 
then yield a small positive incremental effect, but the INMBs still remain negative. At 
an arbitrary willingness to pay of $100 000 per QALY, the INMB is then $-1640 for 
SES and $-4289 for PES, respectively. Accounting for multiple percutaneous 
coronary interventions in individual patients had no qualitative effect on the overall 
cost-effectiveness estimates, neither for SES nor for PES. To explore the effect of 
different time horizons, we calculated the incremental effect and the incremental net 
monetary benefit of DES for time horizons up to 3 years [Figures 4 and 5]. Both DES 
provide positive incremental effects (in QALYs) over a time horizon up to ~2.5 years 
of follow-up. Only SES, however, yield a small positive incremental effect over the full 
time horizon of the analysis (i.e. 3 years). After 2 years there is a decline in 
incremental effects for both DES, which seems to be driven by a trend towards 
increased mortality in patients treated with DES [Figure 4]. Both DES yield a 
negative incremental net monetary benefit for time horizons ranging from 0 to 3 
years, assuming a decision maker’s willingness to pay of $100 000/QALY [Figure 5]. 
The INMB is relatively stable for both DES for time horizons of 1 year and longer.  
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Figure 2A. Cost-effectiveness plane. Incremental costs and effects of the sirolimus-
eluting stent are based on 5 000 Monte Carlo simulations. The point estimate (incremental 
costs $1953; incremental effect  0.001 QALYs) is highlighted.  
 
 
 
Figure 2B. Cost-effectiveness plane. Incremental costs and effects of the paclitaxel-
eluting stent are based on 5 000 Monte Carlo simulations. The point estimate (incremental 
costs $4329; incremental effect -0.002 QALYs) is highlighted.  
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Figure 3. Cost-effectiveness acceptability curves. BMS vs. DES. Base-case analysis 
with a time horizon of 3 years. Results are based on 5 000 Monte Carlo simulations. SES = 
sirolimus-eluting stent, PES = paclitaxel-eluting stent 
 
 
 
Figure 4. Time horizon and incremental effect [QALYs] of DES. SES = sirolimus-
eluting stent, PES = paclitaxel-eluting stent 
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 The DRG reimbursement rates for BMS and DES clearly influence the result. 
At a difference in DRG reimbursement rates of less than $3863 (current difference 
$6760) between BMS and DES, SES yield a positive INMB (at a willingness to pay of 
$100 000/QALY) and would therefore be superior to BMS. At the same threshold 
level, PES yield a positive INMB when the difference in reimbursement rates is less 
than $1400. DES are then likely to be cost-effective.  
 
 
Figure 5. Incremental net monetary benefit (INMB) of DES with different time 
horizons. SES = sirolimus-eluting stent, PES = paclitaxel-eluting stent 
 
In our base case analysis we used average DRG reimbursement rates for 10 top-rated 
US hospitals. In a sensitivity analysis using average DRG reimbursement rates 
derived from a random sample of 10 US hospitals with lower reimbursement rates 
(Table 1), there was no qualitative change in our results. 
 We also explored the robustness of the model towards changes in quality of life 
and used the disutility values for PCI and CABG form a recent health technology 
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assessment report in the United Kingdom (39) disregarding long waiting times that 
are not existent in the United States. In this sensitivity analysis, model results did not 
change the conclusion that would be drawn from the analysis.  
When we applied different commonly used discount rates for both health effects and 
costs ranging from zero to ten percent or when we used differential discounting (i.e. 
using a different discount rate for health effects and costs), we found no major impact 
on the results.  
  
Discussion 
Our results demonstrate that the wide use of DES is not cost-effective and cannot be 
advocated for patients with coronary artery disease similar to those evaluated in the 
pivotal randomized controlled trials comparing BMS to DES. Interestingly, both 
types of evaluated DES showed very small (for SES) or no positive incremental effects 
(for PES) when compared to bare metal stents. At the same time, costs associated 
with DES are higher than costs associated with BMS, and consecutively DES can not 
be considered to be cost-effective.  
The strength of our model is the probabilistic approach and the use of clinical 
effectiveness data from a large comprehensive meta-analysis of 17 trials including 
8221 patients. The effectiveness part of our analysis is supported by the recent 
publications of individual patient data meta-analyses of trials comparing DES to BMS 
(6). No other cost-effectiveness analysis on DES used data from such a large number 
of patients. By relying on clinical effectiveness data from such a large number of 
patients, our model is more precise in predicting clinical outcome events than other 
models relying on smaller number of patients. Furthermore, we integrated 3 years 
follow-up data into our model. This is important since differences in need for target 
vessel revascularizations between patients treated with DES and BMS become 
smaller after the first year of stent implantation, whereas the risk of late stent 
thrombosis remains constant at a rate of 0.6% per year in patients treated with DES 
(43). Therefore, any cost-effectiveness analysis restricting the time horizon to one 
year or calculating the cost per revascularizations avoided in the first year clearly 
results in a biased assessment of the cost-effectiveness of DES. Many of the included 
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trials intend to follow-up patients for 5 years after the index procedure. Our analysis 
based on 3 years follow-up data may not necessarily be extrapolated to an extended 
time horizon since the clinical effectiveness of DES may differ with longer follow-up. 
In our analysis we explicitly took parameter uncertainty into account by fitting 
individual probability distributions to all cost-, quality of life- and epidemiologic 
parameters in the model. This allowed us to perform a Monte Carlo simulation which 
results in an estimate of the probability that DES are cost-effective for a given 
willingness to pay value. The uncertainty concerning the estimates of total health care 
costs and total health effects for both BMS and DES is large. As a consequence, the 
decision uncertainty (i.e. the confidence interval for the estimate of the incremental 
net monetary benefit) is large as well. However, this has no direct influence on the 
conclusion whether DES are cost-effective or not. In a situation where a decision has 
to be taken, the only rational way for a risk-neutral decision maker is to adopt the 
strategy with a positive incremental net monetary benefit. In our analysis DES 
provided a negative INMB and were thus not cost-effective when compared to BMS at 
a willingness to pay up to at least $150 000 per QALY (Figure 3).  
 Further uncertainty arises through methodological and modelling structure 
uncertainty which can be addressed with univariate sensitivity analysis. To assess the 
influence of various other parameters and assumptions on the cost-effectiveness 
estimate we performed univariate (i.e. one-way) sensitivity analyses on various 
parameters and assumptions. Various sensitivity analyses did not result in qualitative 
changes of our results and the model proved to be rather robust. Only marked 
reductions in the difference of DRG reimbursement rates for BMS and DES 
influenced the decision in favour of DES.  
Our analysis has several limitations. Quality of life data were not directly obtained 
from patients enrolled in comparative trials of DES and BMS, but was derived from 
the medical literature. In order to evaluate the importance of these parameters, we 
conducted a sensitivity analysis to evaluate the impact of uncertainty around quality 
of life parameters. Using disutility values per event from a different data source (39), 
did not change the conclusion of our analysis. In our base case, we used the average 
Medicare reimbursement rates and physician fees of ten top-rated cardiology 
hospitals.  For this reason, the results of our analysis may seem limited to patients 
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treated in leading cardiology clinics where treatment costs are usually higher than in 
other hospitals. However, sensitivity analysis using lower reimbursement rates of a 
random sample of 10 US hospitals did not lead to a qualitative different conclusion of 
our analysis and the INMB of DES versus BMS remained negative, thus increasing 
the credibility of our analysis.  
 Our analysis was mainly based on effectiveness data from original pivotal trials 
comparing DES to BMS in patients with symptomatic ischemic discrete de novo 
lesions of ≤ 30 mm length in native coronary arteries with reference vessel diameters 
of 2.5 to 3.75 mm (“on-label use”). However, it is estimated that 60% of current DES 
use in the United States is off-label (44). Thus, our findings can not easily be 
generalized to these more complex patients including patients with acute myocardial 
infarction, multiple vessel disease, long lesions, lesions involving arterial bifurcations 
or the left main coronary artery. The lack of individual patient data precluded the 
conduct of subgroup analyses in patients with diabetes or small vessel disease. Cost-
effectiveness analyses in these subgroups should definitely be conducted in the 
future.  
 Patients enrolled in the SES and PES trials reflect patient populations with 
different baseline risks. In addition, the choice of control stents used in these trials 
was different, and restenoses rates in the control arms of the paclitaxel-eluting stent 
trials were lower than in the control arms of the sirolimus-eluting stent trials. Our 
analysis does therefore not allow any conclusion as to whether the incremental cost-
effectiveness of one of the DES is more favourable than the other. Meta-analyses of 
randomized controlled trials in mixed populations of patients with acute MI and 
coronary heart disease based on direct and indirect comparisons (45) or head to head 
comparisons (46) indicate that SES compared to PES are associated with fewer late 
stent thromboses and revascularisations. Evidence from indirect comparisons, 
however, must be interpreted with care in particular in situations where baseline 
risks in control groups are different between compared pairs (47). Given the higher 
baseline risk and absolute risk reduction from comparative trials of SES to BMS 
versus PES to BMS and considering the caveat expressed above, we do not feel 
comfortable in incorporating evidence form indirect comparisons into our model. 
Furthermore, in light of the results from our study where neither of the 2 DES can be 
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considered cost-effective compared to BMS, the question which of the two DES may 
be the preferred strategy can be considered futile from a decision maker’s 
perspective. 
Our study is the first cost-effectiveness analysis from a US third party payer’s 
perspective to conclude that the broad use of DES in patients with coronary artery 
disease is not cost-effective. Our findings are in conflict with at least five cost-
effectiveness analyses from the US which concluded that DES are attractive economic 
interventions (5). Our results are likely to differ for mainly two reasons. Our model is 
the first to incorporate data from a large meta-analysis including trials identified by a 
systematic, unbiased literature search. In addition, previous studies have not used a 
time horizon that is long enough to take into account the reduced absolute difference 
in need for target vessel revascularizations after the first year of stent implantation.  
Recently, two cost-effectiveness analyses of DES have been published from a Swiss 
and a United Kingdom perspective.  Yet, both of these analyses have their limitations. 
In the BASKET trial, a single center trial with 18 months of follow-up the incremental 
cost-effectiveness ratio of DES was € 40’467 per QALY gained (48). The authors 
concluded that “DES are not good value for money” if implanted in unselected 
patients, but may be cost-effective in patients with small vessel disease or bypass 
graft stenting. This conclusion was based on a subgroup analysis of only 268 patients 
deemed to be at high risk with a limited follow-up of 18 months.  
 In a health technology assessment report from the United Kingdom using 12-
month clinical follow-up data, DES were not cost-effective in a typical NHS 
population, but were considered to be potentially cost-effective in high risk subgroups 
(39). In their analysis the authors assumed no difference in mortality between all 
stent types under analysis. However, from a decision analytic point of view, even 
statistically non-significant differences of effects should be incorporated into an 
analysis (49).  As mentioned above, lack of individual patient data precluded us from 
conducting cost-effectiveness analyses in high risk subgroups. 
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Conclusion 
Contrary to other cost-effectiveness analyses conducted from a US health care 
perspective, our analysis from a US Medicare perspective suggests that DES are not 
cost-effective compared to BMS when implanted in unselected patients with 
symptomatic ischemic coronary artery disease. Only if the difference of DRG 
reimbursement rates for BMS and DES is markedly reduced, the wide use of DES can 
be recommended to a large patient population with symptomatic ischemic coronary 
artery disease.  
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 Cumulative event rates 
Trial N 
Follow-up 
(years) 
Data 
Source* 
 
Cumulative event rates in patients 
treated with SES and BMS† (%) 
     Death MI‡ PCI§ CABG¦ 
RAVEL, 2002 
(50)  
120 
118 
1         P 
SES 
BMS 
1.7 
1.7 
3.3 
5.1 
0 
13.6 
0.8 
0 
  2 CP/PI 
SES 
BMS 
5.0 
2.5 
4.2 
5.1 
1.7 
13.6 
1.7 
0 
  3 CP/PI 
SES 
BMS 
7.5 
4.2 
5.0 
6.8 
3.3 
14.4 
1.7 
0 
SIRIUS, 2003 
(51)  
533 
525 
1 CP/PI 
SES 
BMS 
1.3 
0.8 
3.0 
3.4 
3.6 
6.7 
0.9 
1.7 
  2 P 
SES 
BMS 
2.1 
1.3 
3.6 
3.4 
4.9 
6.9 
1.1 
2.1 
  3 M 
SES 
BMS 
3.9 
2.9 
4.3 
4.8 
11.6 
30.1 
3.0 
5.1 
E-SIRIUS, 2003 
(52)  
175 
177 
1 P 
SES 
BMS 
1.1 
0.6 
4.0 
2.3 
5.1 
26.0 
0.6 
2.3 
  2 PI 
SES 
BMS 
2.3 
2.8 
5.1 
3.4 
5.7 
28.2 
0.6 
2.8 
  3 M 
SES 
BMS 
5.1 
4.0 
5.1 
5.1 
6.9 
31.1 
1.1 
2.8 
C-SIRIUS, 2004 
(53)  
50 
50 
1 CP/PI 
SES 
BMS 
0 
0 
4.0 
4.0 
4.0 
22.0 
2.0 
2.0 
  2 CP/PI 
SES 
BMS 
2.0 
0 
4.0 
4.0 
6.0 
22.0 
4.0 
2.0 
  3 M 
SES 
BMS 
2.0 
0 
6.0 
6.0 
6.0 
22.0 
4.0 
4.0 
SES SMART, 
2004 (54)  
129 
128 
1 PI 
SES 
BMS 
0.8 
3.9 
1.6 
10.2 
28.7 
42.2 
0.8 
4.7 
DIABETES, 2005 
(55)  
80 
80 
1 P/PI 
SES 
BMS 
3.8 
5.0 
2.5 
7.5 
6.3 
33.8 
0 
1.3 
  2 PI 
SES 
BMS 
6.3 
6.3 
3.8 
8.8 
7.5 
33.8 
0 
1.3 
BASKET, 2005 
(15)  
264 
281 
1 P/PI 
SES 
BMS 
3.0 
3.6 
4.2 
5.3 
8.0 
6.4 
1.1 
1.1 
SCANDSTENT, 
2006 (56)  
163 
159 
1 CP/PI 
SES 
BMS 
0.6 
0.6 
1.2 
3.1 
2.5 
30.0 
NA¶ 
NA¶ 
 
 
Table 1A. Cumulative event rates.  
*CP=conference proceeding; M=manufacturer; P=publication; PI=principal investigator 
†SES=sirolimus-eluting stent; BMS=bare-metal stent 
‡nonfatal myocardial infarctions 
§percutaneous coronary intervention 
¦coronary artery bypass graft 
¶not available 
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Cumulative event rates 
Trial N 
Follow-up 
(years) 
Data 
Source* 
 
Cumulative event rates in patients 
treated with SES and BMS† (%) 
     Death MI‡ PCI§ CABG¦ 
TAXUS I, 2003 
(57)  
31 
30 
1 P 
PES 
BMS 
0 
0 
0 
0 
0 
10.0 
0 
3.3 
  2 M 
PES 
BMS 
3.2 
0 
0 
0 
3.2 
10.0 
0 
3.3 
  3 M 
PES 
BMS 
3.2 
0 
0 
0 
3.2 
10.0 
0 
3.3 
TAXUS II MR, 
2003 (58)  
135 
134 
1 P 
PES 
BMS 
0.7 
0.7 
3.7 
5.2 
5.2 
18.7 
0.7 
3.0 
  2 CP/M 
PES 
BMS 
3.0 
1.5 
4.4 
6.0 
6.7 
17.2 
2.2 
3.0 
  3 CP/M 
PES 
BMS 
3.7 
2.2 
5.2 
6.7 
6.7 
20.9 
2.2 
3.0 
TAXUS II SR, 
2003 (58)  
131 
136 
1 P 
PES 
BMS 
0 
1.5 
2.3 
5.1 
6.9 
15.4 
3.1 
0.7 
  2 M 
PES 
BMS 
1.5 
2.2 
3.8 
5.1 
7.6 
19.1 
3.8 
2.2 
  3 M 
PES 
BMS 
4.6 
2.9 
3.8 
5.9 
9.2 
21.3 
3.8 
2.9 
ASPECT, 2003 
(59)  
117 
59 
1 P/PI 
PES 
BMS 
0.9 
0 
2.6 
1.7 
12.0 
8.5 
0.9 
0 
  2 PI 
PES 
BMS 
0.9 
0 
2.6 
1.7 
12.0 
10.2 
0.9 
0 
DELIVER, 
2004 (60)  
517 
512 
1 M 
PES 
BMS 
1.0 
1.4 
1.4 
1.0 
5.4 
6.8 
0.6 
0.8 
ELUTES, 2004 
(61)  
152¶ 
38 
1 P 
PES 
BMS 
0.7 
0 
1.3 
0 
5.9 
13.2 
0.7 
2.6 
  2 PI 
PES 
BMS 
0.7 
0 
1.3 
0 
7.9 
13.2 
1.3 
2.6 
TAXUS IV, 
2004 (62)  
662 
652 
1 P 
PES 
BMS 
2.1 
1.7 
3.3 
4.0 
5.3 
13.5 
1.5 
3.8 
  2 M 
PES 
BMS 
3.6 
3.7 
4.2 
4.6 
8.2 
17.2 
2.1 
4.6 
  3 M 
PES 
BMS 
4.2 
4.1 
5.0 
5.7 
10.3 
18.6 
2.9 
5.1 
TAXUS V de 
novo, 2005 
(63)  
577 
579 
1 P/CP/M 
PES 
BMS 
2.1 
1.7 
4.9 
4.5 
13.9 
18.8 
1.4 
2.6 
TAXUS VI, 
2005 (64)  
219 
227 
1 P/M 
PES 
BMS 
0 
1.8 
8.2 
6.2 
9.6 
18.9 
1.8 
2.2 
  2 CP 
PES 
BMS 
0.5 
2.2 
9.1 
5.7 
12.8 
19.4 
1.8 
3.1 
  3 M 
PES 
BMS 
2.3 
3.1 
9.1 
5.7 
15.5 
19.4 
2.3 
3.1 
BASKET, 2005  
(15)  
281 
281 
 
1 P/PI 
PES 
BMS 
 
3.6 
3.6 
 
3.9 
5.3 
 
4.3 
6.4 
 
1.8 
1.1 
 
Table 1B. Cumulative event rates.  
*CP=conference proceeding; M=manufacturer; P=publication; PI=principal investigator, †SES=sirolimus-eluting stent; 
BMS=bare-metal stent, ‡nonfatal myocardial infarctions, §percutaneous coronary intervention 
¦coronary artery bypass graft; ¶ all DES with various doses of paclitaxel pooled 
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 Baseline event rates and relative risks with standard deviation (SD) 
SES – baseline monthly event probabilities*  
from stent  stent  stent  stent  
to death  MI†  PCI‡  CABG§  
 mean SD mean SD mean SD mean SD 
30 days 0.002639 0.003079 0.018972 0.007175 0.003955 0.005335 0.000660 0.000382 
1st year 0.001141 0.000864 0.001018 0.000880 0.005631 0.003137 0.000660 0.000377 
2nd year 0.001159 0.000878 0.000625 0.000302 0.001696 0.000768 0.000266 0.000437 
3rd year 0.001747 0.000646 0.000487 0.000332 0.000975 0.000340 0.001066 0.000781 
         
PES – baseline monthly event probabilities¦ 
from stent  stent  stent  stent  
to death  MI†  PCI‡  CABG§  
 mean SD mean SD mean SD mean SD 
30 days 0.0028309 0.0035681 0.026917 0.02066 0.006358 0.00881 0.0008905 0.002169 
1st year 0.0011920 0.0008671 0.000707 0.000743 0.006333 0.003136 0.0011593 0.000454 
2nd year 0.0009359 0.0006428 0.000643 0.000392 0.001931 0.000916 0.0004106 0.000263 
3rd year 0.0009388 0.0007865 0.00044 0.00034 0.001525 0.000848 0.0004379 0.000306 
         
SES – relative risk for BMS (SES baseline)¶ 
from stent  stent  stent  stent   
to MI†  PCI‡  CABG§  death  
 mean sd mean sd mean sd mean sd 
30 days 1.08 0.2639 0.86 0.5707 1.75 0.926 1.12 0.6497 
1st year 1.724 0.43465 3.846 0.85917 1.851 0.4155 1.075 0.250144 
2nd year 0.575 0.207755 0.524 0.142096 1.02 0.391797 0.725 0.2128 
3rd year 2.174 0.673777 2.22 0.594536 1.538 0.404037 0.676 0.175134 
         
PES – relative risk for BMS (PES baseline)¶ 
from stent  stent  stent  stent   
to MI†  PCI‡  CABG§  death  
 mean sd mean sd mean sd mean sd 
30 days 0.91 0.2191 0.76 0.3875 1.61 0.7469 1.22 0.4798 
1st year 1.493 0.322771 1.887 0.208206 1.587 0.283296 0.952 0.174795 
2nd year 0.541 0.172268 0.909 0.279675 1.429 0.441276 1.031 0.25909 
3rd year 1.449 0.457121 0.943 0.363275 1.563 0.47847 0.556 0.169068 
         
 
Table 2. Baseline event rates. 
* SES=sirolimus-eluting stent 
† nonfatal myocardial infarctions 
‡ percutaneous coronary intervention 
§ coronary artery bypass graft 
¦PES=paclitaxel-eluting stent 
¶ BMS=bare metal stent 
 
Chapter 5: Drug-eluting stents 
117 
 
 
 
 
Chapter 6: Value of information 
 
 
 
CHAPTER 6: VALUE OF INFORMATION ANALYSIS IN DRUG-ELUTING STENTS 
 
Abstract 
 
Introduction: Currently published studies on the cost-effectiveness of drug eluting 
stents (DES) have not sufficiently addressed parameter uncertainty. In an economic 
evaluation based on a  decision analytic model that accounts for uncertainty in input 
parameters we analysed the cost-effectiveness of the sirolimus-eluting Cypher stent 
(SES) and estimated whether the benefit of a future clinical trial would offset its 
estimated costs.  
 Methods: Based on a decision-analytic Markov model cost-effectiveness estimates 
were derived for SES. Total decision uncertainty was assessed by expected value of 
perfect information (EVPI) analysis. The value of a future clinical trial was analysed 
by means of expected value of sample information analysis. The optimal sample size 
for a future clinical trial was determined by finding the sample size that maximizes 
the expected net benefit of sampling.  
Results: Sirolimus-eluting stents are more costly and slightly more effective than bare 
metal stents. At a decision maker’s willingness to pay of $100 000 per quality-
adjusted life year gained, SES have a 16% probability of being cost-effective. The 
corresponding total decision uncertainty expressed as the EVPI is large, at $205 per 
patient. Clinical parameters that include the baseline event rates and the relative risk 
of events in patient receiving DES contibute most to total decision uncertainty. 
Perfect knowledge of these parameters has an expected value of $7.3 millions per 100 
000 patients. Given the large population size, the expected value of a future trial is 
enormous. The costs of a future trial are by far offset by the value of a trial. The 
optimal sample size for a future trial that would provide more precise clinical 
parameter estimates is 4700 patients over a time horizon of 3 years.  
Conclusion: Based on currently available evidence and the used willingness to pay 
threshold SES have a low probability of being cost-effective. The value of a future trial 
to provide more precise parameter estimates is larger than the costs of conducting 
such a trial. 
 
Chapter 6: Value of information 
 
 
 
Introduction 
 
Numerous clinical trials have shown that drug-eluting stents (DES) reduce in patients 
with symptomatic coronary heart disease restenosis and revascularization rates when 
compared to bare metal stents (BMS)(1). These remarkable achievements have lead 
to dramatic changes in the management of coronary heart disease since the approval 
of DES in April 2003 (1) and DES adoption rates quickly rose to more than 90% in 
some US hospitals (1;2). However, recent reports of late adverse events and stent 
thrombosis prompted caution from regulators and physicians (1-4). It was further 
criticized that the randomized controlled trials on the efficacy of DES have been 
underpowered (3; 5-7).  
 
Acquisition costs of DES are large and therefore, a potential clinical benefit of DES 
may be overshadowed by these costs (8). A review of the literature from 2007 (9) 
identified five cost-effectiveness studies comparing DES to BMS for the United States 
(10-14). Two of the studies are based on randomized controlled trials (10;12), in 3 
studies a decision analytic model was used (11; 13; 14).  
 
Given these limitations and concerns, uncertainty in clinical and cost parameters, 
cost-effectiveness analysis of DES must be scrutinized. However, none of the five 
mentioned US studies explored the decision uncertainty in full depth. In particular, 
none of the decision analytical studies accounted for the uncertainty regarding the 
true value of the input parameters. The two economic analyses (15; 16) that were 
based on a clinical trial used bootstrap resampling methods to assess parameter 
uncertainty.  
 
In this study we examined the cost-effectiveness of the sirolimus-eluting stent (SES) 
compared to BMS with a decision analytic model. We explicitly took parameter 
uncertainty in model input parameters into account and performed a probabilistic 
sensitivity analysis (PSA). PSA provides an estimate of the probability that SES are 
cost-effective for various threshold levels (i.e. willingness to pay values per unit of 
outcome gained)(17-20). A rational risk-neutral decision maker will then adapt the 
strategy with the higher probability of being cost-effective at the decision maker’s 
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threshold value. For any adoption decision that is based on a probability (P) of less 
than 100% (i.e. decision uncertainty is present), there is a 1-P chance that the adopted 
strategy or decision is not cost-effective. The adopted strategy will then lead to a loss 
in monetary terms, health outcomes or both.  
 
To examine the total decision uncertainty we calculated the expected value of perfect 
information (i.e. no uncertainty in model input parameters)(21; 22). The decision 
model has a large number of uncertain input parameters which all can be assigned to 
one of three groups (cost data, clinical data, quality of life data). These groups of 
parameters do not necessarily contribute equally to the overall decision uncertainty. 
In order to identify the magnitude of the individual contribution of groups of 
parameters to the overall decision uncertainty, the expected value of partial perfect 
information (EVPPI) was calculated in a further step for these three groups of 
parameters (23-25). EVPPI places an upper boundary on the value of perfect 
information for groups of parameters.  
 
Usually, more precise parameter estimates will in practice be derived from a clinical 
trial (26; 27). Although very large trials are desirable to obtain very precise parameter 
estimates, the marginal gain in precision may be small at very large sample sizes 
while the marginal costs increase linearly per additionally enrolled patient (28). To 
obtain from a decision maker’s point of view the optimal sample size for a future trial, 
the expected value of the future trial needs to be offset by the costs of the trial. The 
expected net benefit of sampling (ENBS) provides a net monetary value of the future 
trial by subtracting the trial’s costs from its expected value (22). The optimal sample 
size of the future trial can then be estimated by calculating the ENBS for different 
sample sizes.   
 
Methods 
 
The decision model 
 
For this study a previously developed decision analytic model was used. The model is 
presented in detail elsewhere (see chapter 5). In short, the model is a probabilistic, 
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half-cycle corrected Markov model with 5 health states, a cycle length of 1 month and 
a time horizon of 3 years (29; 30). Initially all patients start in the health state “stent” 
– representing patients after the insertion of either a DES or BMS. Every cycle 
patients are at risk of moving to the health states myocardial infarction (MI), 
coronary bypass surgery (CABG), percutaneous coronary intervention or death. 
Age-dependent utility values are assigned to the patients in the model. The decrease 
in health related quality of life in patients with an event is modelled by assigning 
disutility values to patients in an event health state. Quality of life values are derived 
from the ARTs trial (31). Clinical effectiveness data was derived from a large meta-
analysis comprising 17 randomized controlled trials with a follow-up of 3 years (32). 
Unit costs for hospitalizations and surgeries and initial stenting procedures are 
derived from US Medicare diagnosis-related groups (33). The studies perspective is 
the US Medicare payer’s perspective. Costs are in US$ of the financial year 2007. 
Both health effects and costs are discounted at 3% annually (34; 35). For the purpose 
of this study we only focus on the cost-effectiveness of sirolimus eluting stents 
because in our previous analyses these stents were shown to be slightly more 
advantageous than paclitaxel eluting stents when both were compared to BMS. 
 
Analysis of cost-effectiveness 
 
In this cost-utility analysis, health outcomes were measured in terms of quality-
adjusted life years (QALYs). The incremental net monetary benefit statistics were 
used to analyse cost-effectiveness (36).  
 
Probabilistic sensitivity analysis 
 
Beta distributions were assigned to the quality of life and the baseline transition 
probabilities. Truncated normal distributions were used to reflect parameter 
uncertainty in relative risk parameters. Gamma distributions were used for cost 
parameters. The baseline decision was calculated by averaging over 10 000 Monte 
Carlo simulations (20).  
 
Expected value of perfect information 
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The contribution of groups of parameters towards total decision uncertainty was 
calculated with a two-level algorithm for the analysis of expected value of partial 
perfect information (23; 25). Given the two levels of uncertainty (uncertainty in the 
parameters of interest and in the remaining parameters) a two-level Monte Carlo 
simulation was applied with 400 inner level and 400 outer level simulations. 
 
Estimation of the value of the future trial 
 
The value of the future trial is calculated as the expected value of sample information 
(EVSI)(37). Detailed descriptions of the method can be found elsewhere (22; 37). 
EVSI is measured by the reduction in expected opportunity loss and can be calculated 
for a particular sample size from the prior information used to calculate EVPI and an 
estimate of the sample variance. Assuming that the net health benefit of the SES and 
the BMS is normally distributed, the unit normal loss integral can be used for the 
calculation. To obtain the population EVSI, EVSI per patient for a particular sample 
size is multiplied by the incidence of patients entering the decision problem.  
 
Costs of the future trial and optimal sample size 
 
The costs of the future trial comprise fixed costs (e.g. for data management and 
analysis) and variable reporting costs. Fixed costs were estimated to be $700 000 for 
a NIH-sponsored clinical trial carried out in an academic medical center (28). 
Reporting costs depend on the number of patients enrolled and were estimated to be 
$700 per patient.  
The sample size for the future trial will be optimal where the marginal benefit of 
additional sample information is equal to the marginal cost of sampling (i.e. the 
optimal sample size is found by identifying the sample size that maximizes 
ENBS)(22). 
 
The model was developed and analysed with Microsoft Excel and Visual Basic 6.5. 
For all analyses a threshold level of $100’000/QALY was assumed.  
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Results 
 
Cost-effectiveness analysis 
 
Total health related costs were higher in DES patients than in BMS patients (Table 1). 
At the same time DES are slightly more effective than BMS. The incremental cost-
effectiveness ratio (the incremental costs over the incremental effect) is > 2 millions. 
$ per QALY. For threshold values of $50 000 and $100 000 this yields a negative 
incremental net monetary benefit. However, the results are far from being significant. 
The decision uncertainty is large as can be seen from the spread of the joint density 
distribution over the four quadrants and from the relatively large 95% confidence 
intervals (Figure 1, Table 1).   
 
 
 
 
Figure 1. Cost effectiveness plane. Shown are 5 000 incremental cost/effect pairs 
derived from a Monte Carlo simulation. The point estimated ($1953, 0.001 QALYs) is 
highlighted.  
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Results (mean values and 95% confidence intervals) 
BMS* 
costs [$] 
BMS* 
effect 
[QALYs†] 
DES‡ 
costs [$] 
DES‡ 
effect 
[QALYs†] 
∆costs [$] ∆effect [QALYs†] 
ICER§ 
[$/QALY†] 
26253 
(24615 to 
28084) 
2.358 
(2.324 to 
2.378) 
28207 
(27513 to 
29015) 
2.359 
(2.334 to 
2.376) 
1953 (-14 
to 3779) 
0.001 (-
0.032 to 
0.038) 
> 
2 000 000 
INMB¶ @ 
$50 000 [$] 
INMB¶ @ 
$100 000 [$] 
P (INMB>0) 
@ $50 000 
P (INMB>0) 
@ $100 000 
EVPI¤ per 
patient @ 
$50 000 [$] 
EVPI¤ per 
patient @ 
$100 000 [$] 
-1914 (-4442 
to 795 
-1875 (-5646 
to 2497) 7.5% 16.2% 53 205 
  
Table 1. Results. * BMS = Bare metal stent; † QALY = quality-adjusted life year; ‡ DES = 
drug-eluting stent; § ICER = incremental cost-effectiveness ratio;  ¶ INMB = incremental net 
monetary benefit; ¤ EVPI = expected value of perfect information 
 
 
Total decision uncertainty 
 
If we assume the decision maker’s willingness to pay (i.e. threshold value) is $50 000 
or $100 000 per quality-adjusted life year, DES have a probability of being cost-
effective of 7.5% and 16.2%, respectively (Table 1). Thus, given the higher threshold 
value, the chance of making the wrong decision by adopting a strategy that is not 
cost-effective is 16.2%. The cost-effectiveness acceptability curve (Figure 2) provides 
further probability values for threshold values ranging from $0 to $150 000. 
Additionally, figure 2 shows the total expected value of perfect information per 
patient. As for the threshold values that were analysed, the probability that DES are 
cost-effective increases, but never reaches a value of more than 50%, likewise the 
expected value of perfect information increases over the range of threshold values 
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analysed. At a threshold value of $100 000/QALY total EVPI per patient is $205 
(Table 1).  
 
  
 
 
 
Figure 2. Cost-effectiveness acceptability curve (CEAC) and expected value of 
perfect information (EVPI) per patient. P = probability that DES are cost-effective  
 
 
Expected value of perfect information for parameter groups 
 
Figure 3 shows the expected value of partial perfect information for 3 groups of 
parameters. Clinical parameters that include the baseline event rates and the relative 
risk of events in patient receiving SES contibute the most to total decision 
uncertainty. Perfect knowledge of these parameters has an expected value of $7.3 
millions per 100 000 patients. EVPPI for the quality of life parameters is $3.1 
millions per 100 000 patients and $0.56 millions per 100 000 patients for the cost 
parameters.  
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Figure 3. Expected value of partial perfect information for three groups of 
parameters.  
 
 
Value of a future clinical trial 
 
The expected value of sample information is enormous. Even for a small trial with 
less than a thousand patients, the expected value of that trial is more than $40 
billions (Figure 4). This value exceeds by far the costs of conducting a trial for all 
sample sizes that were analyzed. The optimal sample size of the future clinical trial is 
found by calculating the sample size that maximises the expected net benefit of 
sampling (i.e. the difference between the value of the trial and its costs). For sample 
sizes larger than 2000 patients (1000 patients per arm) the marginal gain in sample 
information per additional patient is small and diminishing. Thus, ENBS already 
reaches a maximum at 4700 patients which would be the optimal sample size for a 
future clinical trial.    
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Figure 4. Population EVSI and expected costs and benefits of sampling. EVSI = 
expected value of sample information (value of the trial); ENBS = expected net benefit of 
sampling (EVSI – Cs); Cs = cost of sampling (cost of the trial). The optimal sample size of 
4700 patients is highlighted through the horizontal dashed line.  
 
 
Size of the population 
 
The base case analysis was calculated for 554 400 patients eligible for stenting per 
year and a time horizon of 3 years based on data from the Centers for Disease 
Control. Because the population size directly influences the value of a future trial, the 
optimal sample size also depends on the population size. Figure 5 shows the optimal 
sample size for a population sizes up to 2 million patients per 3 years (the time 
horizon of the study). As expected, a larger population size increases the optimal 
sample size for the future trial.  
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Figure 5. Population size and corresponding optimal sample size of the future 
clincal trial. Size of the trial shown as total number of enrolled patients 
 
Discussion 
 
Within this study the cost-effectiveness of the sirolimus-eluting stent compared to 
bare metal stents was analysed from a US Medicare payer’s perspective. Although the 
clinical input data used for this study was based on data from a meta-analysis with 
more than 8 000 patients, the question of the cost-effectiveness of the sirolimus-
eluting stent cannot be answered satisfactorily due to the large decision uncertainty. 
At a decision maker’s willingness to pay value of $100 000 per quality-adjusted life 
year gained, the optimal decision would be not to adopt drug-eluting stents from a 
health economic perspective. Still, there remains a chance of about 16% that this 
decision would be wrong. Although a 84% chance of making the right decision may 
seem acceptable, this value in itself is insufficient for rational decision making. In an 
economic evaluation usually data from bootstrap analysis or a Monte Carlo 
simulation are presented on the cost-effectiveness plane and summarized by the cost-
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effectiveness acceptability curve (Figure 2). The CEAC provides information on the 
probability of making the wrong decision but not about the consequences of making 
the wrong decision (38). Given a potentially harmful intervention that increases 
patients’ mortality or an intervention that is very costly, the resulting loss in 
monetary terms and/or health outcome that would arise by making the wrong 
decision may be substantial.  
 
To reduce decision uncertainty, a rational decision maker may thus wish to base the 
decision on a more sound evidence base. EVPPI analysis provides information on the 
contribution of single parameters or groups of parameters towards total decision 
uncertainty. Hence, EVPPI allows to identify those parameters for which further 
information is of highest value to reduce total decision uncertainty. In many 
situations, further information will only be available from clinical trials. Given that 
the cost of conducting a clinical trial is large (28) and increases with sample size, the 
net benefit of the future clinical trial will ultimately yield diminishing marginal 
returns with increasing sample size. The optimal sample size for the future clinical 
trial is thus found by identifying the sample size that maximizes ENBS.  
 
In this evaluation on the cost-effectiveness of the SES we estimated the optimal 
sample size for a future clinical trial that would inform this decision is 4700 patients. 
The time horizon of this analysis was identical with the time horizon of the decision 
analytic model (3 years). Although in future the second generation of drug-eluting 
stents will likely dominate the market, SES may well be used for many years to come. 
Consequently the eligible patient population would increase manyfold, thus yielding a 
larger optimal trial size for the future clinical trial.  
 
Although this study showed that conducting a future clinical SES trial is worthwhile 
given the positive ENBS, this does not necessarily mean that this trial should be 
carried out. Given the limited amount of resources for clinical research, the net 
benefit of the proposed trial needs to be compared to the net benefit of other 
proposed trials with a potentially higher ENBS (26). Furthermore the proposed trial 
may exceed the budget available for clinical research. The proposed trial with 4700 
patients would cost close to $17 millions.  
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EVPPI and ENBS analyses are new techniques that build on currently employed 
methods for the analysis of parameter uncertainty (39).  Whether the concept of 
EVPPI and ENBS will be understood and adopted by decision makers and agencies 
that decide on the reimbursement of health care technologies and on funding of 
future clinical research has to be seen and investigated. To date, only very few studies 
have been published that employ these methods. Therefore, important aspects of 
these methods are not yet fully established. It is probably possible to predict the 
number of patients eligible for stenting in the year 2018, but whether these patients 
will then receive a first-generation sirolimus-eluting stent is unknown. ENBS analysis 
that employs a long time horizon may thus overestimate the optimal sample size for a 
future clinical trial to inform sirolimus-eluting stents’ cost-effectiveness.  
 
Nevertheless, even for a short time horizon – as applied in this study - ENBS analysis 
showed that conducting a future DES clinical trial will be worth its cost in light of the 
uncertainty of cost-effectiveness estimates for DES and of long-term safety and 
efficacy data. However, we would like to stress that the results of our ENBS analysis 
should not be interpreted ‘to halt expediting the approval of novel products but to 
require larger, longer-term post-marketing studies, particularly for permanent 
medical-device implants’ (40). In conclusion, value of information analysis offers a 
framework to support decision maker’s in identifying the right trial size for future 
studies seen worthwhile to be pursued.    
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CHAPTER 7: DISCUSSION 
 
A detailed discussion of the findings of each study and its implications for clinical 
practice and medical decision making have been given at the end of each chapter. 
Here, a more general discussion of the methods and findings will be given.  
 
Within this thesis  the cost-effectiveness of three different health care interventions 
has been assessed in economic evaluation studies. Economic evaluations provide 
information on the expected health benefit and expected costs of novel interventions 
and are, thus of interest to decision makers, reimbursement  and health technology 
assessment agencies.  
 
Since the seminal study by Neuhauser and Lweiki published in the New England 
Journal of Medicine in 1975 (1), the progress in methodology and the number of 
economic evaluations published has increased enormously. Although the basic 
methodology did not change over time, numerous analytical and statistical 
techniques have been developed – and some of them abolished – since then.  
 
The development of the methodology of health economic analyses and its rigorous 
application was also supported by the rise of evidence based medicine that underwent 
a similar development at the same time (2).  
 
The widespread use of computer technology and the continuous improvement in 
computer software and hardware can also be attributed to the progress of  economic 
evaluation methodology and  the position economic analyses have reached to day (3). 
Advanced Bayesian statistical techniques, on which probabilistic sensitivity analysis 
and value of information analysis are based, have contributed significantly to feel and 
go back to the original ideas of  reverend Thomas Bayes more than 200 years ago (4). 
But only now, with the availability of modern computers and standard spreadsheet 
packages, these methods are within reach for many scientists.  
 
Although trial-based economic evaluations are still carried out, many economic 
evaluations published to date are now based on decision analytic models (5). Given 
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the complexity of decision problems, the variety of available data and the truncated 
time horizon of randomized controlled trials, only decision analytic models meet all 
requirements for economic evaluation for decision making (5). Further, by univariate 
and probabilistic sensitivity analysis, decision analytic models allow to truly address 
methodological and parameter uncertainty.  Different types of decision analytic 
models exist to date, but all models rely on decision analysis, probability theory and 
expected utility theory (6). 
 
The model type is in principle determined by the research question that the model is 
set up to inform. For evaluations of interventions and therapies for which the timing 
of events and effects is fully captured within a short period of time, decision trees are 
the appropriate model type. A decision tree model was used in the study of chapter 
one, to analysis the cost-effectiveness of extending prophylactic fondaparinux 
treatment for patients undergoing hip fracture surgery and total hip replacement . An 
adverse event that may result from such a surgical procedure is  deep vein 
thrombosis. As a thrombosis caused by the surgical intervention will only be expected 
within the first 30 days after the initial intervention, the timing of events in the 
fondaparinux cost-effectiveness analysis is largely irrelevant. This provided the 
rational for using a decision tree model in the fondaparinux study.  
 
In contrast, the exact estimation of the timing of events was an important part of the 
Markov models developed for the risedronate and the drug-eluting stents cost-
effectiveness analyses (see chapter 3 and 5). It is well established that the 
bisphosphonate risedronate is effective in preventing fractures in osteoporotic 
women of older age with a reduced bone density. From epidemiological data it is also 
well known, that the fracture risk at different fracture site (e.g. at the hip, vertebra, 
wrist) increases with the patients’ age. Many of the clinical trials that analyzed the 
efficacy of bisphosphonates had inclusion criteria that only allowed to enroll women 
from a certain age range.  
 
In order to model the effectiveness of risedronate treatment and to assess 
risedronate’s cost-effectiveness a Markov model was the appropriate choice. The 
model allowed to model time-dependent characteristics of the patients (risk of 
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natural death, baseline quality of life; disutility per fracture), the treatment (offset 
time) and the disease (fracture rates). Because the time horizon for this analysis was a 
lifetime time horizon, also costs in later years could be discounted and thus estimated 
by their net present value.       
 
 Timing did also play an important role in the economic evaluation of the sirolimus- 
and the paclitaxel-eluting stent (chapter 5). Although the actual time horizon in the 
analysis was short, the Markov model structure was useful to not only examine the 
cost-effectiveness of drug eluting stents 3 years after stent implantation, but also 
allowed to calculate the incremental effect for every time horizon between zero and 3 
years. In a sensitivity analysis, the model thus confirmed the expected decline in the  
effectiveness of drug eluting stents 2 to 3 years following  the initial stent insertion (7-
10).   
 
The use of decision analytic models in economic evaluations has another advantage 
over the use of trials as the vehicle for an economic evaluation. Probabilistic decision 
models allow to calculate the expected value of partial perfect information. Hence, it 
is possible to identify the contribution of individual parameters towards total decision 
uncertainty. Based on the cost-utility model for drug-eluting stents, presented in 
chapter 5, the value of perfect information to inform the adoption decision of 
sirolimus-eluting stents was calculated (see chapter 6).  
 
Unsurprisingly, given the ongoing debate about the safety and efficacy of drug-eluting 
stents, it was found that uncertainty in the clinical model input parameters 
contributes  most to total decision uncertainty. In an extension of this analysis it was 
estimated by means of expected net benefit of sampling analysis, that a future clinical 
trial would provide valuable information.   
 
In conclusion, economic evaluations based on decision analytic models represent  a 
systematic approach to decision making under uncertainty, and provide decision 
makers with relevant information on cost-effectiveness estimates and the value of 
further research (6; 11-13).   
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The classical conclusion “further research is needed” is often  found in the discussion 
section of many research papers. In economic evaluations with expected net benefit 
of sample information analysis and positive expected net benefit of sampling, such 
statements in the future may well be extended by the quote “and will most likely be 
cost-effective.”  
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Appendix 
 
 
APPENDIX 
 
Useful Excel functions 
Function and syntax Description 
abs (number) returns the absolute value of a number 
average(number1; number2;...) returns the arithmetic mean 
betainv(probability; alpha; beta) returns the inverse of the cumulative beta prob. function 
exp(number) returns e raised to the power of number 
gammainv(probability; α;β) 
 
returns the inverse of the gamma cumulative distribution 
if(logical test; value if true; v. if false) returns value based on logical test 
indirect(reference text; A1) returns the reference specified by a text string 
large(array;k) returns the k-th largest value in a data set 
ln(number) returns the natural logarithm of a number 
max(number1; number2;....) returns the largest value in a set of values 
min(number1; number2;...) returns the smallest number in a set of values 
norminv(probability; mean; SD) returns the inverse of the normal cumulative distribution 
rand() 
 
returns an evenly distributed random real number 
round(A1;2) rounds a number to a specified number of digits 
small(array;k) returns the k-th smallest value in a data set 
sqrt(number) returns a positive square root 
stdev(number1; number2;...) estimates standard deviation based on a sample 
sum(A1:A5) adds all the numbers specified as arguments 
var(number1; number2;…) returns the variance of a set of values 
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VBA code for EVPPI calculation 
 
Public Sub EVPPI_two_level() 
 
Worksheets("evppi").Range("g4:g1010").Clear 
noofouterruns = 5 
noofinnerruns = 1000 
 
For outer = 1 To noofouterruns 
 
'clear results 
Worksheets("evppi").Range("c4:d1010").Clear 
Worksheets("evppi").Range("c1:d2").Clear 
 
'sample parameter of interest 
Worksheets("qol").Range("d1").Value = "on" 
calculate 
Worksheets("qol").Range("d1").Value = "off" 
 
'sample other parameters 
Worksheets("costs").Range("g1").Value = "on" 
Worksheets("rr").Range("ak1").Value = "on" 
Worksheets("transp").Range("ai1").Value = "on" 
 
        For i = 1 To noofinnerruns 
            calculate 
            nbbms = Worksheets("results").Range("d26").Value 
            nbdes = Worksheets("results").Range("d28").Value 
            Worksheets("evppi").Range("c" & i + 3).Value = nbbms 
            Worksheets("evppi").Range("d" & i + 3).Value = nbdes 
        Next i 
 
'calculate average 
Worksheets("evppi").Range("c1").Value = "=average(c4:c1003)" 
Worksheets("evppi").Range("d1").Value = "=average(d4:d1003)" 
calculate 
 
'choose highest and record 
highestinner = Worksheets("evppi").Range("e1").Value 
Worksheets("evppi").Range("g" & outer + 3).Value = highestinner 
Next outer 
 
calculate 
 
End Sub
 
 
Selected abstracts 
141 
 
 
SELECTED ABSTRACTS 
 
Bischof M, Lim M, Ferrusi I, Burke N, Blackhouse G, Goeree R, Tarride JE. R there any 
differences between Excel and R? Comparison of ICER estimates and CEACs obtained from a 
model implemented in Microsoft Excel and R. ISPOR 12th Annual European Congress, 
October 2009, Paris, France 
Bischof M, Lim M, Ferrusi I, Burke N, Blackhouse G, Goeree R, Tarride JE. Some results 
are more equal than others: comparison of ICER estimates and CEACs obtained from a 
model implemented in Microsoft Excel and TreeAge. 31st Annual Meeting of the Society for 
Medical Decision Making, October 2009, Hollywood, California  
Bischof M, Briel M, Bucher HC, Nordmann A. Drug-eluting stents from a medicare payer 
perspective: cost-utlility analysis with 4-year clinical meta-analysis data. ISPOR 13th Annual 
International Meeting, May 2008, Toronto, Canada 
Bischof M. Expected Value of Partial Perfect Information: Application of a 2-level algorithm 
in a drug-eluting stent decision analytic model. 29th Annual Meeting of the Society for 
Medical Decision Making, October 2007, Pittsburgh, USA 
Bischof M. Expected value of perfect information: an application to a decision analytic cost-
utility model for a novel therapy in cardiology.  European Association of Decision Making 
21st conference on Subjective Probability, Utility and Decision Making , August 2007, 
Warsaw, Poland 
 
Bischof M. Expected value of perfect information: an application to a decision analytic cost-
effectiveness model for drug eluting stents. iHEA 6th World Congress on Health Economics, 
July 2007, Copenhagen, Denmark 
 
Bischof M, Briel M, Bucher HC, Nordmann A. Economic evaluation of drug eluting stents: 
cost-utility analysis. ISPOR 9th Annual European Congress, October 2006, Copenhagen, 
Denmark 
Bischof M. “Expected Value of Perfect Information” for osteoporosis cost-utility analysis. 
Would it pay off to know more? European Science Foundation – The Kiel Institute for the 
World Economy Conference on the Global Health Economy, October 2006, Salzau, Germany 
Bischof M. Expected Value of Perfect Information Calculations in Health Economics. 51. 
Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und 
Epidemiologie, September 2006, Leipzig, Germany 
Bischof  M, Kraenzlin M, Sendi P. Cost-effectiveness of risedronate for the treatment of 
osteoporosis in Swiss postmenopausal women. iHEA 6th European Conference on Health 
Economics, July 2006, Budapest, Hungary 
Bischof M, Sendi P, Leuppi J. Cost-effectiveness of an extended four-week fondaparinux 
prophylaxis regimen for the prevention of thromboembolic events in patients undergoing 
major orthopedic surgery. ISPOR 8th Annual European Congress, November 2005, Florence, 
Italy  
Curriculum Vitae 
 
 
CURRICULUM VITAE 
 
 
EDUCATION  
 
 
10/03 – 09/04  MSc Health Economics, University of York, England.  Thesis title: “Cost-
effectiveness of neonatal ECMO based on seven year results from the UK 
Collaborative ECMO Trial”, published in Pediatrics 2006 
 
09/95 to 03/02 Pharmacy degree (equivalent MPharm), Westfaelische-Wilhelms-
University, Muenster, Germany, and professional licence as a pharmacist 
(Approbation) 
 
 
MILITARY SERVICE 
 
07/94 to 06/95  German Armed Forces 
 
 
LICENSURE 
 
03/02   Pharmacist (German license)  
 
 
FIELDS OF INTEREST 
 
Economic Evaluations 
Decision Analytic Modelling 
PSA & Value of Information Analysis 
Evidence Synthesis 
Clinical Epidemiology 
Resource Allocation 
 
 
 
WORK EXPERIENCE 
 
09/08 to present Post-doctoral Research Fellow, Programs for Assessment of Technology in 
Health (PATH) Research Institute, McMaster University, Hamilton, ON, 
Canada  
 
11/04 to 06/08 Research Fellow, Basel Institute for Clinical Epidemiology and Biostatistics, 
University Hospital Basel, Basel, Switzerland 
 
05/02 – 08/03 Pharmacist, Apotheke des Westens (community pharmacy), Berlin, Germany 
 
04/02 Pharmacist, Barbara Apotheke (community pharmacy), Kamen, Germany 
 
11/00 – 10/01    Junior Pharmacist, Panorama Apotheke (community pharmacy), Berlin, 
Germany 
 
 
 
Curriculum Vitae 
143 
 
 
OTHER PROFESSIONELL EXPERIENCES 
 
07/08 to present Associated Research Fellow, Basel Institute for Clinical Epidemiology and 
Biostatistics, University Hospital Basel, Basel, Switzerland 
 
07/08 to 08/08 Visiting Fellow, Programs for Assessment of Technology in Health (PATH) 
research institute, McMaster University, Hamilton, ON, Canada 
 
04/06 to 06/08  Research Fellow, Swiss Tropical Institute, University of Basel, Switzerland 
 
2006   Investigator, European network for Health Technology Assessment 
 
2005 Health economic reviewer for Swiss Medical Weekly 
 
07/04 – 09/04     Research Fellow, National Perinatal Epidemiology Unit, University of 
Oxford, England 
 
12/03, 05/04 York Health Economics Consortium Ltd., York, England 
 
09/03 Summer Session in Microeconomics, University of York, England 
 
08/99 3M Health Care, Loughborough, England 
 
11/98 – 12/98 Institute for Pharmaceutical Technology, University of Muenster, Germany 
 
 
MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES 
 
International:  iHEA, International Health Economics Association, since 2005 
   ISPOR, International Society for Pharmacoeconomics & Outcomes Research, 
   since 2005 
   SMDM, Society for Medical Decision Making, since 2005 
    
 
National:  GMDS, Deutsche Gesellschaft für Medizinische Informatik, Biometrie und 
   Epidemiologie, since 2005 
   DPhG, Deutsche Pharmazeutische Gesellschaft, since 2000 
 
 
PEER-REVIEWING FOR SCIENTIFIC CONFERECES  
 
Judge for poster sessions and oral presentations, 2009 ISPOR 12th Annual European Congress 
 
Abstract reviewer, 2010 ISPOR 15th Annual International Meeting 
Abstract reviewer, 2010 ECHE 8th European Conference on Health Economics 
Abstract reviewer, 2009 ISPOR 14th Annual International Meeting 
Abstract reviewer, 2008 ECHE 7th European Conference on Health Economics 
Abstract reviewer, 2007 ISPOR 10th Annual European Congress 
Abstract reviewer, 2007 ISPOR 12th Annual International Meeting 
Abstract reviewer, 2006 ISPOR 9th Annual European Congress 
 
 
 
 
Curriculum Vitae 
144 
 
 
 
 
EDITORIAL POSITIONS 
 
Member of the Editorial Board, Medical Decision Making, 3 years term, since 2009 
 
Reviewer, Archives of Internal Medicine, since 2010 
Reviewer, Canadian Journal of Cardiology, since 2009 
Reviewer, PharmacoEconomics, since 2008 
Reviewer, Journal of the American College of Radiology, since 2008 
Reviewer, Value in Health, since 2007 
Reviewer, Medical Decision Making, since 2007 
 
 
PUBLICATIONS  
 
Bischof M, Kraenzlin M, Bucher HC, Sendi P. Cost-effectiveness of risedronate for the prevention 
and treatment of osteoporosis in Swiss postmenopausal women. The Open Pharmacoeconomics & 
Health Economics Journal. 2010. 2, 25-33. 
 
Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O’Reilly D, Xie F, 
Goeree R. Economic evaluations of treatments for diabetes mellitus. A review of methods used in 
long-term cost-effectiveness models of diabetes treatment. PharmacoEconomics.28(4):255-277, April 
1, 2010   
 
Tarride JE, Burke N, Bischof M, Hopkins R, Goeree L, Campbell K, Goeree R. A review of health 
utilities across conditions common in pediatric and adult poplulations. Health and Quality of Life 
Outcomes. 2010 Jan 27;8(1):12. 
 
Tarride JE, Blackhouse G, Bischof M, McCarron EC, Lim M, Ferrusi I, Xie F, Goeree R.  Approaches 
to economic evaluations of healthcare technologies. J Am Coll Radiol. 2009 May;6(5):307-16. 
    
Goeree R, Levin L, Chandra K, Bowen JM, Blackhouse G, Tarride JE, Burke N, Bischof M, Xie, F. 
O’Reilly D.  Health technology assessment and primary data collection for reducing decision making 
uncertainty.  J Am Coll Radiol. 2009 May;6(5):332-42. 
 
Bischof M, Briel M, Bucher HC, Nordmann A. Cost-effectiveness of drug eluting stents in a US 
setting: a cost-utility analysis with 3 year clinical follow-up data. Value in Health, 2009,12(5):649-
656.  
 
Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H. Cost-effectiveness of neonatal 
ECMO based on seven year results from the UK Collaborative ECMO Trial. Pediatrics, 2006 May; 
117(5):1640-9 
 
Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism prophylaxis 
with fondaparinux in hip surgery patients. Expert Review of Pharmacoeconomics & Outcomes 
Research, April 2006, Vol. 6, No. 2 
 
Bischof M, Sendi P. How much bone for the buck? The importance of compliance issues in economic 
evaluations of bisphosphonates. Expert Review of Pharmacoeconomics & Outcomes Research, Aug 
2005, Vol. 5, No. 4 
 
 
 
Curriculum Vitae 
145 
 
 
PEER-REVIEWED ORAL PRESENTATIONS 
 
Bischof M, Lim M, Ferrusi I, Burke N, Blackhouse G, Goeree R, Tarride JE. R there any differences 
between Excel and R? Comparison of ICER estimates and CEACs obtained from a model 
implemented in Microsoft Excel and R. ISPOR 12th Annual European Congress, October 2009, Paris, 
France 
 
Bischof M. Expected Value of Partial Perfect Information: Application of a 2-level algorithm in a 
drug-eluting stent decision analytic model. 29th Annual Meeting of the Society for Medical Decision 
Making, October 2007, Pittsburgh, USA 
 
Nordmann A, Bischof M, Briel M, Bucher HC. Cost-effectiveness of drug eluting stents in a US 
setting: cost-utility analysis with a decision analytic model using meta-analysis data with 3 year 
follow-up. European Society of Cardiology Congress 2007, September 2007, Vienna, Austria 
 
Bischof M. Expected Value of Perfect Information Calculations in Health Economics.  
51. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und 
Epidemiologie, September 2006, Leipzig, Germany 
 
Bischof M, Sendi P. Choice of parametric distributions in decision analytic models and expected value 
of perfect information. Accepted oral presentation. iHEA 6th European Conference on Health 
Economics, July 2006, Budapest, Hungary 
 
 
INVITED PRESENTATIONS 
 
Bischof M, Blackhouse G, Goeree R, Xie F. Value of Information: Vision of Ingenuity or Venture of 
Icarus? Workshop at the 2010 Canadian Agency for Drugs and Technology in Health Symposium, 18 
– 20 April 2010, Halifax, Canada 
 
 
POSTERS 
 
Bischof M, Lim M, Ferrusi I, Burke N, Blackhouse G, Goeree R, Tarride JE. Some results are more 
equal than others: comparison of ICER estimates and CEACs obtained from a model implemented in 
Microsoft Excel and TreeAge. 31st Annual Meeting of the Society for Medical Decision Making, 
October 2009, Hollywood, California  
 
Bischof M, Brogan A, Cavassini M, Bernasconi E, Furrer H, Vernazza P, Hirschel B, Weber R, 
Battegay M, Bucher HC and the Swiss HIV Cohort Study. Cost-effectiveness of first line antiretroviral 
backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. 5th 
International Aids Society’s Conferecence on HIV Pathogenesis, Treatment and Prevention, July 2009, 
Cape Town, South Africa 
 
Bischof M, Briel M, Bucher HC, Nordmann A. Drug-eluting stents from a medicare payer 
perspective: cost-utlility analysis with 4-year clinical meta-analysis data. ISPOR 13th Annual 
International Meeting, May 2008, Toronto, Canada 
 
Bischof M. Analysis of uncertainty in economic evaluations in health care: expected value of perfect 
information for drug-eluting stents. BioValley Science Day, October 2007, Basel, Switzerland 
 
Leuppi J, Bischof M. Cost-effectiveness of eNO measurements in chronic asthma management. 
European Respiratory Society’s 17th Annual Congress, September 2007, Stockholm, Sweden 
 
Curriculum Vitae 
146 
 
 
Bischof M. Expected value of perfect information: an application to a decision analytic cost-utility 
model for a novel therapy in cardiology.  European Association of Decision Making 21st conference on 
Subjective Probability, Utility and Decision Making , August 2007, Warsaw, Poland 
 
Bischof M. Expected value of perfect information: an application to a decision analytic cost-
effectiveness model for drug eluting stents. Accepted for iHEA 6th World Congress on Health 
Economics, July 2007, Copenhagen, Denmark 
 
Bischof M, Briel M, Bucher HC, Nordmann A. Economic evaluation of drug eluting stents: cost-
utility analysis. ISPOR 9th Annual European Congress, October 2006, Copenhagen, Denmark 
 
Bischof M. “Expected Value of Perfect Information” for osteoporosis cost-utility analysis. Would it 
pay off to know more? European Science Foundation – The Kiel Institute for the World Economy 
Conference on the Global Health Economy, October 2006, Salzau, Germany 
 
Bischof  M, Kraenzlin M, Sendi P. Cost-effectiveness of risedronate for the treatment of osteoporosis 
in Swiss postmenopausal women. iHEA 6th European Conference on Health Economics, July 2006, 
Budapest, Hungary 
 
Bischof M, Sendi P, Leuppi J. Cost-effectiveness of an extended four-week fondaparinux prophylaxis 
regimen for the prevention of thromboembolic events in patients undergoing major orthopedic 
surgery. ISPOR 8th Annual European Congress, November 2005, Florence, Italy  
 
 
 
ELECTRONIC LETTERS 
 
Bischof M, Certainty about uncertainty. http://www.bmj.com/cgi/eletters/334/7594/621#163441. 4 
April 2007 
 
 
PRESENTATIONS 
 
Some results are more equal than others: comparison of Excel, R and TreeAge for decision analytic 
modelling, Centre for the Ecaluation of Medicine, Hamilton, December 2010 
 
Modelling in economic evaluation: an unavoidable fact of life. McMaster University, Hamilton, 
December 2010 
 
VBA programming in Microsoft Excel. PATH Research Institute, September 2009 
 
The things they don’t teach you at grad school: getting the most out of TreeAge and Excel. PATH 
Research Institute, September 2009 
 
(Almost) all you need to know about cost-effectiveness analysis. Basel Institute for Clinical 
Epidemiology, February 2008 
 
Expected value of perfect information: the example of drug-eluting stents, McMaster University, 
Canada, November 2007 
 
Probabilistic Sensitivity Analysis: Initial results from the malaria model, Technical Advisory Group 
for the Malaria Modelling Project, Swiss Tropical Institute, June 2007 
 
Curriculum Vitae 
147 
 
 
Cost-utility analysis of eNO measurements in chronic asthma management, 2nd SWISS NO 
MEETING, University Hospital Basel, May 2007 
 
Limitations of the Acceptability Curve, Basel Institute for Clinical Epidemiology, May 2007 
 
Cost-effectiveness of drug-eluting stents in a US setting: cost-utility analysis with a decision analytic 
model using meta-analysis data with 3 year follow-up, Swiss Tropical Institute, February 2007 
 
Gesundheitsökonomische Evaluationen [Health economic evaluations], Department of Philosophy, 
University of Basel, January 2007 
 
Cost-effectiveness of eNO measurements in chronic asthma management, Pneumology Department, 
University Hospital Basel, November 2006 
 
Evaluating Uncertainty, Training workshop on the Manual of Implementation, Intermittent Preventive 
Treatment in Infants (IPTi) Cost-Effectiveness Working Group (CEWG), Swiss Tropical Institute, 
November 2006 
 
Probabilistic Sensitivity Analysis and Value of Information, Technical Advisory Group for the 
Malaria Modelling Project, Swiss Tropical Institute, November 2006 
 
Economic Evaluation of Drug Eluting Stents, European Network for Health Technology Assessment, 
Working Package 4 meeting, Basel, November 2006 
 
A decision analytic model for the evaluation of the cost-effectveness of drug eluting stents, European 
Network for Health Technology Assessment, Working Package 4 meeting, Helsinki, September 2006  
 
Expected Value of Perfect Information Calculations in Health Economics, Swiss Tropical Institute, 
Basel, May 2006 
 
Expected Value of Perfect Information Calculations in Health Economics, Basel Institute for Clinical 
Epidemiology, University Hospital Basel, Basel, December 2005 
 
Interpreting the Cost-Effectiveness Acceptability Curve, Basel Institute for Clinical Epidemiology, 
University Hospital Basel, January 2005 
 
 
 
TEACHING  
 
Clinical Epidemiology (to 3rd year medical students), University of Basel, May 2008 
Calculations with a scientific calculator, HCMTC 2008, STI, February 2008 
Diagnostic Tests (to 6th year medical students), University of Basel, December 2007 
Meta-Analysis (to 6th year medical students), University of Basel, November 2007 
Clinical Epidemiology (to 3rd year medical students), University of Basel, June 2007 
Meta-Analysis (to 6th year medical students), University of Basel, November & December 2006 
Critical Appraisal, European Center of Pharamceutical Medicine, University of Basel, July 2006 
Clinical Epidemiology (to 3rd year medical students), University of Basel, June 2006 
Clinical Epidemiology (to 3rd year medical students), University of Basel, June 2005 
 
 
GRANTS 
 
Travel Grant, Canadian Agency for Drugs and Technologies in Health, April 2010 
Curriculum Vitae 
148 
 
 
Post-doctoral research grant, Amgen Canada Inc., direct funds: CAN$ 75 000, September 2009 
Post-doctoral research grant, Amgen Canada Inc., direct funds: CAN$ 75 000, September 2008 
Travel Grant, European Network for Health Technology Assessment, 2006 
Conference Grant, European Science Foundation, 2006 
Travel Grant, University of Basel, 2006 
 
 
 
 
  
 
  
Curriculum Vitae 
150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
